

## Contents

### Company information

Breakdown of capital	1
----------------------	---

### Individual financial statements

Balance sheet - Assets	2
------------------------	---

Balance sheet - Liabilities	3
-----------------------------	---

Statement of income	5
---------------------	---

Statement of comprehensive income	6
-----------------------------------	---

Statement of cash flows (Indirect method)	7
---	---

#### Statement of changes in shareholders' equity

Statement of changes in shareholders' equity (DMPL) - 01/01/2025–03/31/2025	8
---	---

Statement of changes in shareholders' equity (DMPL) – 01/01/2024–03/31/2024	9
---	---

Statement of added value	10
--------------------------	----

### Consolidated financial statements

Balance sheet - Assets	11
------------------------	----

Balance sheet - Liabilities	12
-----------------------------	----

Statement of income	14
---------------------	----

Statement of comprehensive income	15
-----------------------------------	----

Statement of cash flows (Indirect method)	16
---	----

#### Statement of changes in shareholders' equity

Statement of changes in shareholders' equity (DMPL) - 01/01/2025–03/31/2025	17
---	----

Statement of changes in shareholders' equity (DMPL) – 01/01/2024–03/31/2024	18
---	----

Statement of added value	19
--------------------------	----

Performance comment	20
---------------------	----

Notes to the financial statements	46
-----------------------------------	----

Other information the Company deems to be relevant	74
--	----

### Opinions and Statements

Special review report - Unqualified	77
-------------------------------------	----

Statement of the Executive Officers on the Financial Statements	78
---	----

Statement of the Directors on Independent Auditor's Report	79
--	----

Company information / Breakdown of capital

Quantity of shares (Unit)	Current quarter 03/31/2025
Paid-in capital	
Common	552,495,663
Preferred	0
Total	552,495,663
Treasury	
Common	6,930,377
Preferred	0
Total	6,930,377

**Individual financial statements / Balance sheet – Assets****(In thousands of reais)**

<b>Code of account</b>	<b>Account description</b>	<b>Current quarter 03/31/2025</b>	<b>Prior year 12/31/2024</b>
1	Total assets	2,183,611	2,067,888
1.01	Current assets	547,143	409,557
1.01.01	Cash and cash equivalents	20,321	15,783
1.01.02	Interest earning bank deposits	443,876	327,637
1.01.02.01	Interest earning bank deposits measured at fair value through profit or loss	305,218	192,982
1.01.02.01.04	Free investments	305,218	192,982
1.01.02.03	Interest earning bank deposits measured at amortized cost	138,658	134,655
1.01.02.03.01	Investments that guarantee technical reserves	38,264	37,251
1.01.02.03.02	Free investments	100,394	97,404
1.01.03	Accounts receivable	54,174	51,202
1.01.03.01	Clients	25,823	25,501
1.01.03.01.06	Assets of insurance and reinsurance contracts	25,823	25,501
1.01.03.02	Other accounts receivable	28,351	25,701
1.01.06	Recoverable taxes	23,518	7,364
1.01.06.01	Current taxes recoverable	23,518	7,364
1.01.06.01.01	Tax and social security credits	23,518	7,364
1.01.07	Prepaid expenses	5,254	7,571
1.01.07.20	Other	5,254	7,571
1.02	Non-current assets	1,636,468	1,658,331
1.02.01	Non-current receivables	628,779	644,932
1.02.01.03	Interest earning bank deposits measured at amortized cost	538,771	539,081
1.02.01.03.01	Investments that guarantee technical reserves	137,942	139,379
1.02.01.03.03	Free investments	400,829	399,702
1.02.01.07	Deferred taxes	8,302	25,879
1.02.01.07.01	Deferred income tax and social contribution	8,302	25,879
1.02.01.10	Other non-current assets	81,706	79,972
1.02.01.10.03	Judicial and tax deposits	33,019	32,104
1.02.01.10.04	Other credits receivable	13,698	13,697
1.02.01.10.06	Tax and social security credits (recoverable taxes)	34,989	34,171
1.02.02	Investments	80,724	86,656
1.02.02.01	Equity interest	80,724	86,656
1.02.02.01.02	Interest in subsidiaries	76,150	82,309
1.02.02.01.03	Joint ownership	4,573	4,346
1.02.02.01.04	Other investments	1	1
1.02.03	Property, plant and equipment	27,367	29,345
1.02.03.01	Construction in progress	16,812	18,313
1.02.03.02	Right-of-use in lease	10,555	11,032
1.02.04	Intangible assets	899,598	897,398
1.02.04.01	Intangible assets	899,598	897,398

**Individual financial statements - Balance sheet - Liabilities****(In thousands of reais)**

<b>Code of account</b>	<b>Account description</b>	<b>Current quarter 03/31/2025</b>	<b>Prior year 12/31/2024</b>
2	Total liabilities	2,183,611	2,067,888
2.01	Current liabilities	693,632	725,553
2.01.01	Social and labor obligations	63,876	57,620
2.01.01.02	Labor obligations	63,876	57,620
2.01.01.02.01	Salaries, vacation and fees	63,876	57,620
2.01.02	Suppliers	37,817	31,413
2.01.02.01	Domestic suppliers	37,817	31,413
2.01.02.01.01	Trading on operations	18,372	11,675
2.01.02.01.02	Suppliers of goods and services	11,247	11,495
2.01.02.01.03	Other debits from health care operations	1,302	1,071
2.01.02.01.04	Consideration/premiums to be repaid	164	45
2.01.02.01.07	Anticipated revenue from consideration/premiums	6,732	7,127
2.01.03	Tax liabilities	28,746	39,986
2.01.03.01	Federal tax liabilities	25,739	37,273
2.01.03.01.01	Income tax and social contribution payable	5,915	15,952
2.01.03.01.02	Other federal tax liabilities	19,824	21,321
2.01.03.03	Municipal tax liabilities	3,007	2,713
2.01.05	Other liabilities	563,193	596,534
2.01.05.02	Other	563,193	596,534
2.01.05.02.01	Dividends and interest on own capital payable	263,875	261,213
2.01.05.02.05	Other accounts payable	24,835	36,076
2.01.05.02.12	Liabilities from insurance and reinsurance contracts	272,499	297,287
2.01.05.02.13	Lease liabilities	1,984	1,958
2.02	Non-current liabilities	125,515	114,566
2.02.02	Other liabilities	50,898	47,339
2.02.02.02	Other	50,898	47,339
2.02.02.02.03	Other liabilities	14,897	14,767
2.02.02.02.04	Fees payable	91	0
2.02.02.02.07	Lease liabilities	10,959	11,460
2.02.02.02.12	Other accounts payable	24,951	21,112
2.02.04	Provisions	74,617	67,227
2.02.04.01	Tax, social security, labor and civil provisions	74,617	67,227
2.02.04.01.01	Tax provisions	29,716	28,882
2.02.04.01.02	Social security and labor provisions	1,389	1,304
2.02.04.01.04	Civil provisions	43,512	37,041
2.03	Shareholders' equity	1,364,464	1,227,769
2.03.01	Realized capital	851,017	851,017
2.03.02	Capital reserves	-35,610	-35,610
2.03.02.10	Goodwill/negative goodwill in capital transaction	-35,610	-35,610
2.03.04	Profit reserves	412,854	420,718
2.03.04.01	Legal reserve	127,428	127,428
2.03.04.07	Tax incentive reserve	129	129
2.03.04.08	Additional dividend proposed	81,000	81,000
2.03.04.09	Treasury shares	-79,436	-71,572
2.03.04.10	Statutory Reserve of Regulatory Capital	100,000	100,000

**Individual financial statements - Balance sheet - Liabilities****(In thousands of reais)**

<b>Code of account</b>	<b>Account description</b>	<b>Current quarter 03/31/2025</b>	<b>Prior year 12/31/2024</b>
2.03.04.11	Investment and expansion reserve	183,733	183,733
2.03.05	Retained earnings/losses	144,975	0
2.03.06	Equity valuation adjustments	-801	-795
2.03.07	Accumulated translation adjustments	2,038	2,755
2.03.08	Other comprehensive income	-10,009	-10,316

**Individual financial statements / Statement of income****(In thousands of reais)**

Code of account	Account description	Accumulated of the current year	Accumulated of the prior year
		01/01/2025–03/31/2025	01/01/2024–03/31/2024
3.01	Revenue from sales of goods and/or services	572,801	531,106
3.01.07	Insurance revenue (PAA)	443,468	409,733
3.01.08	Insurance revenue (BBA)	129,333	121,373
3.02	Cost of goods and/or services sold	-335,028	-347,007
3.02.08	Insurance costs	-335,028	-347,007
3.03	Gross income	237,773	184,099
3.04	Operating expenses/revenue	-7,576	615
3.04.02	General and administrative expenses	-13,951	-12,410
3.04.02.01	Administrative expenses	-12,898	-12,131
3.04.02.05	Income (loss) from disposal or write-off of non-current asset items and other	-1,053	-279
3.04.04	Other operating revenue	8,974	12,547
3.04.04.01	Other operating revenues from Health care plans	8,846	12,428
3.04.04.02	Revenues from health care plans for the Operator	128	119
3.04.05	Other operating expenses	-4,426	-5,370
3.04.05.02	Provision for credit losses	723	141
3.04.05.03	Profit sharing	-5,149	-5,511
3.04.06	Equity in net income of subsidiaries	1,827	5,848
3.05	Income (loss) before financial income and taxes	230,197	184,714
3.06	Financial income (loss)	15,001	23,494
3.06.01	Financial revenues	31,140	35,378
3.06.02	Financial expenses	-16,139	-11,884
3.07	Income (loss) before income tax	245,198	208,208
3.08	Income tax and social contribution	-75,474	-61,471
3.08.01	Current	-58,033	-68,234
3.08.02	Deferred	-17,441	6,763
3.09	Net income (loss) from continued operations	169,724	146,737
3.11	Income/loss for the period	169,724	146,737
3.99	Earnings per share - (Reais R\$ / Shares)		
3.99.01	Basic earnings per share		
3.99.01.01	COMMON SHARES	0.31097	0.26559
3.99.02	Diluted earnings per share		
3.99.02.01	COMMON SHARES	0.31097	0.26559

**Individual financial statements / Statement of comprehensive income****(In thousands of reais)**

Code of account	Account description	Accumulated of the current year	Accumulated of the prior year
		01/01/2025–03/31/2025	01/01/2024–03/31/2024
4.01	Net income for the period	169,724	146,737
4.02	Other comprehensive income	-416	-4,126
4.02.01	Accumulated translation adjustment	-717	571
4.02.03	Other comprehensive income of investees recognized under the equity method	41	-68
4.02.04	Other comprehensive income	266	-4,636
4.02.05	Equity valuation adjustments of investees recognized under the equity method.	-6	7
4.03	Comprehensive income for the period	169,308	142,611

**Individual financial statements / Statement of cash flows (Indirect method)****(In thousands of reais)**

Code of account	Account description	Accumulated of the current year	Accumulated of the prior year
		01/01/2025–03/31/2025	01/01/2024–03/31/2024
6.01	Net cash from operational activities	51,025	49,154
6.01.01	Cash generated in operations	258,512	212,161
6.01.01.01	Net income (loss) for the period	169,724	146,737
6.01.01.02	Depreciation and amortization	12,889	12,051
6.01.01.03	Net inflation adjustments	942	-2,848
6.01.01.05	Provision for lawsuits	980	460
6.01.01.06	Income (loss) from disposal of non-current assets and other	1,053	279
6.01.01.07	Equity in net income of subsidiaries	-1,827	-5,848
6.01.01.08	Provision for credit losses	-723	-141
6.01.01.11	Income tax and social contribution	75,474	61,471
6.01.02	Changes in assets and liabilities	-207,487	-163,007
6.01.02.01	Interest earning bank deposits measured at fair value through profit or loss	-112,236	-166,976
6.01.02.03	Other accounts receivable, recoverable taxes and prepaid expenses	-10,983	44,810
6.01.02.05	Long-term assets (Non-current)	82	2,578
6.01.02.06	Assets and liabilities of insurance and reinsurance contracts	-23,984	3,841
6.01.02.09	Tax obligations (taxes payable)	-1,203	-925
6.01.02.10	Labor obligations, suppliers, and other accounts payable	-4,474	2,563
6.01.02.11	Non-current liabilities	7,208	5,743
6.01.02.13	Income tax and social contribution paid	-68,071	-52,163
6.01.02.15	Trading on operations	6,697	-2,469
6.01.02.16	Interest paid	-523	-9
6.02	Net cash used in investment activities	-16,282	-30,560
6.02.01	Acquisition of property, plant and equipment	-20	-135
6.02.02	Acquisition of intangible assets	-14,144	-13,327
6.02.07	Dividends received from Subsidiaries and jointly-controlled subsidiaries	1,575	4,625
6.02.11	Interest earning bank deposits measured at amortized cost	-3,693	-21,723
6.03	Net cash from financing activities	-30,205	-20,253
6.03.01	Dividends and interest on own capital paid	-21,642	-19,580
6.03.02	Acquisition of own shares - Treasury	-7,864	0
6.03.05	Payment of Lease	-699	-673
6.05	Increase (decrease) in cash and cash equivalents	4,538	-1,659
6.05.01	Opening balance of cash and cash equivalents	15,783	13,615
6.05.02	Closing balance of cash and cash equivalents	20,321	11,956



**Individual financial statements / Statement of changes in shareholders' equity / DMPL - 01/01/2025–03/31/2025****(In thousands of reais)**

Code of account	Account description	Paid-up capital	Capital reserves, Options granted and Treasury shares	Profit reserves	Retained earnings (loss)	Other comprehensive income	Shareholders' equity
5.01	Opening balances	851,017	-107,182	492,290	0	-8,356	1,227,769
5.02	Prior-year adjustments	0	0	0	0	0	0
5.03	Adjusted opening balances	851,017	-107,182	492,290	0	-8,356	1,227,769
5.04	Capital transactions with partners	0	-7,864	0	-24,749	0	-32,613
5.04.04	Treasury shares acquired	0	-7,864	0	0	0	-7,864
5.04.07	Interest on own capital	0	0	0	-24,749	0	-24,749
5.05	Total comprehensive income	0	0	0	169,724	-416	169,308
5.05.01	Net income for the period	0	0	0	169,724	0	169,724
5.05.02	Other comprehensive income	0	0	0	0	-416	-416
5.05.02.04	Translation adjustments in the period	0	0	0	0	-717	-717
5.05.02.06	Equity valuation adjustments of investees recognized under the equity method.	0	0	0	0	-6	-6
5.05.02.08	Other comprehensive income	0	0	0	0	266	266
5.05.02.09	Other comprehensive income of investees recognized under the equity method	0	0	0	0	41	41
5.06	Internal changes in shareholders' equity	0	0	0	0	0	0
5.07	Closing balances	851,017	-115,046	492,290	144,975	-8,772	1,364,464

**Individual financial statements / Statement of changes in shareholders' equity / DMPL – 01/01/2024–03/31/2024****(In thousands of reais)**

Code of account	Account description	Paid-up capital	Capital reserves, Options granted and Treasury shares	Profit reserves	Retained earnings (loss)	Other comprehensive income	Shareholders' equity
5.01	Opening balances	851,017	-35,610	561,679	0	9,908	1,386,994
5.02	Prior-year adjustments	0	0	0	0	0	0
5.03	Adjusted opening balances	851,017	-35,610	561,679	0	9,908	1,386,994
5.04	Capital transactions with partners	0	-22,179	0	-22,779	0	-44,958
5.04.04	Treasury shares acquired	0	-22,179	0	0	0	-22,179
5.04.07	Interest on own capital	0	0	0	-22,779	0	-22,779
5.05	Total comprehensive income	0	0	0	146,737	-4,126	142,611
5.05.01	Net income for the period	0	0	0	146,737	0	146,737
5.05.02	Other comprehensive income	0	0	0	0	-4,126	-4,126
5.05.02.04	Translation adjustments in the period	0	0	0	0	571	571
5.05.02.06	Equity valuation adjustments of investees recognized under the equity method.	0	0	0	0	7	7
5.05.02.08	Other comprehensive income	0	0	0	0	-4,636	-4,636
5.05.02.09	Other comprehensive income of investees recognized under the equity method	0	0	0	0	-68	-68
5.06	Internal changes in shareholders' equity	0	0	0	0	0	0
5.07	Closing balances	851,017	-57,789	561,679	123,958	5,782	1,484,647

**Individual financial statements / Statement of added value****(In thousands of reais)**

Code of account	Account description	Accumulated of the	Accumulated of the prior
		current year 01/01/2025–03/31/2025	year 01/01/2024–03/31/2024
7.01	Revenues	573,524	531,247
7.01.01	Sale of goods, products and services	572,801	531,106
7.01.04	Formation/reversal of allowance for doubtful accounts	723	141
7.02	Inputs acquired from third parties	-258,510	-268,940
7.02.01	Cost of products, goods and services sold	-215,342	-220,768
7.02.02	Materials, energy, third-party services and other	-4,429	-4,706
7.02.04	Other	-38,739	-43,466
7.02.04.01	Other operating revenues (expenses)	2,844	-3,300
7.02.04.03	Administrative expenses	-41,583	-40,166
7.03	Gross added value	315,014	262,307
7.04	Retentions	-12,889	-12,051
7.04.01	Depreciation, amortization and depletion	-12,889	-12,051
7.05	Net added value produced	302,125	250,256
7.06	Added value received as transfer	32,967	41,226
7.06.01	Equity in net income of subsidiaries	1,827	5,848
7.06.02	Financial revenues	31,140	35,378
7.07	Total added value payable	335,092	291,482
7.08	Distribution of added value	335,092	291,482
7.08.01	Personnel	37,379	38,498
7.08.01.01	Direct remuneration	29,385	30,020
7.08.01.02	Benefits	6,189	6,719
7.08.01.03	Severance Pay Fund (FGTS)	1,805	1,759
7.08.02	Taxes, duties and contributions	111,448	94,176
7.08.02.01	Federal	102,302	86,184
7.08.02.02	State	1	17
7.08.02.03	Municipal	9,145	7,975
7.08.03	Third-party capital remuneration	16,541	12,071
7.08.03.02	Rentals	402	187
7.08.03.03	Other	16,139	11,884
7.08.04	Remuneration of own capital	169,724	146,737
7.08.04.01	Interest on own capital	24,749	22,779
7.08.04.03	Retained earnings / Loss for the period	144,975	123,958

**Consolidated financial statements / Balance sheet – Assets****(In thousands of reais)**

<b>Code of account</b>	<b>Account description</b>	<b>Current quarter 03/31/2025</b>	<b>Prior year 12/31/2024</b>
1	Total assets	2,235,903	2,122,069
1.01	Current assets	618,940	490,076
1.01.01	Cash and cash equivalents	21,617	16,531
1.01.02	Interest earning bank deposits	476,273	357,791
1.01.02.01	Interest earning bank deposits measured at fair value through profit or loss	337,615	223,136
1.01.02.01.04	Free investments	337,615	223,136
1.01.02.03	Interest earning bank deposits measured at amortized cost	138,658	134,655
1.01.02.03.01	Investments that guarantee technical reserves	38,264	37,251
1.01.02.03.02	Free investments	100,394	97,404
1.01.03	Accounts receivable	77,575	85,065
1.01.03.01	Clients	29,836	33,316
1.01.03.01.07	Assets of insurance and reinsurance contracts	29,836	33,316
1.01.03.02	Other accounts receivable	47,739	51,749
1.01.04	Inventories	6	56
1.01.06	Recoverable taxes	30,896	15,853
1.01.06.01	Current taxes recoverable	30,896	15,853
1.01.06.01.01	Tax and social security credits	30,896	15,853
1.01.07	Prepaid expenses	5,963	8,690
1.01.07.20	Other	5,963	8,690
1.01.08	Other current assets	6,610	6,090
1.01.08.03	Other	6,610	6,090
1.01.08.03.02	Assets held for sale	6,610	6,090
1.02	Non-current assets	1,616,963	1,631,993
1.02.01	Non-current receivables	638,203	653,691
1.02.01.03	Interest earning bank deposits measured at amortized cost	538,771	539,081
1.02.01.03.01	Investments that guarantee technical reserves	137,942	139,379
1.02.01.03.02	Free investments	400,829	399,702
1.02.01.07	Deferred taxes	15,445	32,346
1.02.01.07.01	Deferred income tax and social contribution	15,445	32,346
1.02.01.10	Other non-current assets	83,987	82,264
1.02.01.10.03	Judicial and tax deposits	34,313	33,435
1.02.01.10.04	Other credits receivable	14,286	14,268
1.02.01.10.06	Tax and social security credits (recoverable taxes)	35,388	34,561
1.02.02	Investments	6,364	6,121
1.02.02.01	Equity interest	6,364	6,121
1.02.02.01.01	Interest in associated companies	1,735	1,719
1.02.02.01.04	Joint ownership	4,573	4,346
1.02.02.01.05	Other investments	56	56
1.02.03	Property, plant and equipment	50,354	52,154
1.02.03.01	Construction in progress	28,575	30,438
1.02.03.02	Right-of-use in lease	21,779	21,716
1.02.04	Intangible assets	922,042	920,027
1.02.04.01	Intangible assets	922,042	920,027

**Consolidated financial statements / Balance sheet - Liabilities****(In thousands of reais)**

<b>Code of account</b>	<b>Account description</b>	<b>Current quarter 03/31/2025</b>	<b>Prior year 12/31/2024</b>
2	Total liabilities	2,235,903	2,122,069
2.01	Current liabilities	730,749	764,626
2.01.01	Social and labor obligations	77,509	69,765
2.01.01.02	Labor obligations	77,509	69,765
2.01.01.02.01	Salaries, vacation and fees	77,509	69,765
2.01.02	Suppliers	42,476	36,361
2.01.02.01	Domestic suppliers	42,476	36,361
2.01.02.01.01	Trading on operations	18,439	11,732
2.01.02.01.02	Suppliers of goods and services	15,839	16,386
2.01.02.01.03	Other debits from health care operations	1,302	1,071
2.01.02.01.04	Consideration/premiums to be repaid	164	45
2.01.02.01.07	Anticipated revenue from consideration/premiums	6,732	7,127
2.01.03	Tax liabilities	34,383	47,600
2.01.03.01	Federal tax liabilities	30,880	44,262
2.01.03.01.01	Income tax and social contribution payable	6,299	16,735
2.01.03.01.02	Other federal tax liabilities	24,581	27,527
2.01.03.03	Municipal tax liabilities	3,503	3,338
2.01.05	Other liabilities	576,381	610,900
2.01.05.02	Other	576,381	610,900
2.01.05.02.01	Dividends and interest on own capital payable	263,875	261,213
2.01.05.02.05	Other accounts payable	31,315	43,514
2.01.05.02.12	Liabilities from insurance and reinsurance contracts	274,164	299,398
2.01.05.02.13	Lease liabilities	7,027	6,775
2.02	Non-current liabilities	140,381	129,210
2.02.02	Other liabilities	62,226	57,925
2.02.02.02	Other	62,226	57,925
2.02.02.02.03	Other liabilities	15,498	15,351
2.02.02.02.04	Fees payable	91	0
2.02.02.02.07	Lease liabilities	18,766	19,010
2.02.02.02.11	Taxes and charges payable	294	303
2.02.02.02.12	Other accounts payable	27,577	23,261
2.02.04	Provisions	78,155	71,285
2.02.04.01	Tax, social security, labor and civil provisions	78,155	71,285
2.02.04.01.01	Tax provisions	31,018	30,185
2.02.04.01.02	Social security and labor provisions	3,620	4,045
2.02.04.01.04	Civil provisions	43,517	37,055
2.03	Consolidated shareholders' equity	1,364,773	1,228,233
2.03.01	Realized capital	851,017	851,017
2.03.02	Capital reserves	-35,610	-35,610
2.03.02.10	Goodwill/negative goodwill in capital transaction	-35,610	-35,610
2.03.04	Profit reserves	412,854	420,718
2.03.04.01	Legal reserve	127,428	127,428
2.03.04.07	Tax incentive reserve	129	129
2.03.04.08	Additional dividend proposed	81,000	81,000
2.03.04.09	Treasury shares	-79,436	-71,572

**Consolidated financial statements / Balance sheet - Liabilities****(In thousands of reais)**

<b>Code of account</b>	<b>Account description</b>	<b>Current quarter 03/31/2025</b>	<b>Prior year 12/31/2024</b>
2.03.04.10	Statutory Reserve of Regulatory Capital	100,000	100,000
2.03.04.11	Investment and expansion reserve	183,733	183,733
2.03.05	Retained earnings/losses	144,975	0
2.03.06	Equity valuation adjustments	-801	-795
2.03.07	Accumulated translation adjustments	2,038	2,755
2.03.08	Other comprehensive income	-10,009	-10,316
2.03.09	Non-controlling interest	309	464

**Consolidated financial statements / Statement of income****(In thousands of reais)**

Code of account	Account description	Accumulated of the current year	Accumulated of the prior year
		01/01/2025–03/31/2025	01/01/2024–03/31/2024
3.01	Revenue from sales of goods and/or services	587,800	554,501
3.01.02	Sales of goods and services	13,737	13,871
3.01.05	Taxes on sales of goods and services	-3,249	-3,623
3.01.07	Insurance revenue (PAA)	447,979	422,880
3.01.08	Insurance revenue (BBA)	129,333	121,373
3.02	Cost of goods and/or services sold	-332,100	-345,470
3.02.08	Insurance costs	-332,100	-345,470
3.03	Gross income	255,700	209,031
3.04	Operating expenses/revenue	-24,057	-21,783
3.04.01	Sales expenses	-1,431	-1,972
3.04.01.01	Sales expenses	-1,431	-1,972
3.04.02	General and administrative expenses	-30,132	-27,252
3.04.02.01	Administrative expenses	-29,079	-26,927
3.04.02.05	Income (loss) from disposal or write-off of non-current asset items and other	-1,053	-325
3.04.04	Other operating revenue	9,655	13,292
3.04.04.01	Other operating revenues from Health care plans	9,555	13,173
3.04.04.02	Health care revenues not related to the Operator's health plans	100	119
3.04.05	Other operating expenses	-3,927	-6,907
3.04.05.02	Provision for credit losses	2,750	112
3.04.05.03	Profit sharing	-6,220	-6,620
3.04.05.04	Long-term incentive program (ILP)	-457	-399
3.04.06	Equity in net income of subsidiaries	1,778	1,056
3.05	Income (loss) before financial income and taxes	231,643	187,248
3.06	Financial income (loss)	15,170	23,625
3.06.01	Financial revenues	32,251	36,246
3.06.02	Financial expenses	-17,081	-12,621
3.07	Income (loss) before income tax	246,813	210,873
3.08	Income tax and social contribution	-77,244	-64,184
3.08.01	Current	-60,683	-71,156
3.08.02	Deferred	-16,561	6,972
3.09	Net income (loss) from continued operations	169,569	146,689
3.11	Income/loss for the period	169,569	146,689
3.11.01	Attributed to the Parent company's partners	169,724	146,737
3.11.02	Attributed to non-controlling partners	-155	-48
3.99	Earnings per share - (Reais R\$ / Shares)		
3.99.01	Basic earnings per share		
3.99.01.01	COMMON SHARES	0.31097	0.26559
3.99.02	Diluted earnings per share		
3.99.02.01	COMMON SHARES	0.31097	0.26559

**Consolidated financial statements / Statement of comprehensive income****(In thousands of reais)**

Code of account	Account description	Accumulated of the current year	Accumulated of the prior year
		01/01/2025–03/31/2025	01/01/2024–03/31/2024
4.01	Consolidated net income for the period	169,569	146,689
4.02	Other comprehensive income	-416	-4,126
4.02.01	Accumulated translation adjustment	-723	578
4.02.03	Other comprehensive income of investees recognized under the equity method	41	-68
4.02.04	Other comprehensive income	266	-4,636
4.03	Consolidated comprehensive income for the period	169,153	142,563
4.03.01	Attributed to the Parent company's partners	169,308	142,611
4.03.02	Attributed to non-controlling partners	-155	-48



**Consolidated financial statements / Statement of cash flows (Indirect method)****(In thousands of reais)**

Code of account	Account description	Accumulated of the current year	Accumulated of the prior year
		01/01/2025–03/31/2025	01/01/2024–03/31/2024
6.01	Net cash from operational activities	53,469	53,406
6.01.01	Cash generated in operations	260,229	222,047
6.01.01.01	Net income (loss) for the period	169,569	146,689
6.01.01.02	Depreciation and amortization	14,932	14,345
6.01.01.03	Net inflation adjustments	1,006	-2,816
6.01.01.05	Provision for lawsuits	953	488
6.01.01.06	Disposal of non-current assets and other	1,053	325
6.01.01.07	Equity in net income of subsidiaries	-1,778	-1,056
6.01.01.08	Provision for credit losses	-2,750	-112
6.01.01.11	Income tax and social contribution	77,244	64,184
6.01.02	Changes in assets and liabilities	-206,760	-168,641
6.01.02.01	Interest earning bank deposits measured at fair value through profit or loss	-114,479	-167,594
6.01.02.03	Other accounts receivable, recoverable taxes and prepaid expenses and other current assets	-8,806	44,003
6.01.02.04	Inventories	50	1,422
6.01.02.05	Long-term assets (Non-current)	207	2,526
6.01.02.06	Assets and liabilities of insurance and reinsurance contracts	-18,874	-1,955
6.01.02.09	Tax obligations (taxes payable)	-2,781	-1,414
6.01.02.10	Labor obligations, suppliers, and other accounts payable	-2,975	6,415
6.01.02.11	Long-term liabilities (Non-current liabilities)	5,671	5,181
6.01.02.13	Income tax and social contribution paid	-70,925	-54,737
6.01.02.15	Trading on operations	6,707	-2,467
6.01.02.17	Interest paid	-555	-21
6.02	Net cash used in investment activities	-16,740	-33,839
6.02.01	Acquisition of property, plant and equipment	-444	-397
6.02.02	Acquisition of intangible assets	-14,178	-13,344
6.02.07	Dividends received from Subsidiaries and jointly-controlled subsidiaries	1,575	1,625
6.02.11	Interest earning bank deposits measured at amortized cost	-3,693	-21,723
6.03	Net cash from financing activities	-31,643	-21,106
6.03.01	Dividends and interest on own capital paid	-21,642	-19,726
6.03.02	Acquisition of own shares - Treasury	-7,864	0
6.03.05	Payment of Lease	-2,137	-1,380
6.05	Increase (decrease) in cash and cash equivalents	5,086	-1,539
6.05.01	Opening balance of cash and cash equivalents	16,531	14,391
6.05.02	Closing balance of cash and cash equivalents	21,617	12,852

**Consolidated financial statements / Statement of changes in shareholders' equity / DMPL - 01/01/2025–03/31/2025****(In thousands of reais)**

Code of account	Account description	Paid-up capital	Capital reserves, Options granted and Treasury shares	Profit reserves	Retained earnings (loss)	Other comprehensive income	Shareholders' equity	Non-controlling interest	Consolidated shareholders' equity
5.01	Opening balances	851,017	-107,182	492,290	0	-8,356	1,227,769	464	1,228,233
5.02	Prior-year adjustments	0	0	0	0	0	0	0	0
5.03	Adjusted opening balances	851,017	-107,182	492,290	0	-8,356	1,227,769	464	1,228,233
5.04	Capital transactions with partners	0	-7,864	0	-24,749	0	-32,613	0	-32,613
5.04.04	Treasury shares acquired	0	-7,864	0	0	0	-7,864	0	-7,864
5.04.07	Interest on own capital	0	0	0	-24,749	0	-24,749	0	-24,749
5.05	Total comprehensive income	0	0	0	169,724	-416	169,308	-155	169,153
5.05.01	Net income for the period	0	0	0	169,724	0	169,724	-155	169,569
5.05.02	Other comprehensive income	0	0	0	0	-416	-416	0	-416
5.05.02.04	Translation adjustments in the period	0	0	0	0	-723	-723	0	-723
5.05.02.08	Other comprehensive income	0	0	0	0	266	266	0	266
5.05.02.09	Other comprehensive income of investees recognized under the equity method	0	0	0	0	41	41	0	41
5.06	Internal changes in shareholders' equity	0	0	0	0	0	0	0	0
5.07	Closing balances	851,017	-115,046	492,290	144,975	-8,772	1,364,464	309	1,364,773

**Consolidated financial statements / Statement of changes in shareholders' equity / DMPL – 01/01/2024–03/31/2024****(In thousands of reais)**

Code of account	Account description	Paid-up capital	Capital reserves, Options granted and Treasury shares	Profit reserves	Retained earnings (loss)	Other comprehensive income	Shareholders' equity	Non-controlling interest	Consolidated shareholders' equity
5.01	Opening balances	851,017	-35,610	561,679	0	9,908	1,386,994	680	1,387,674
5.02	Prior-year adjustments	0	0	0	0	0	0	0	0
5.03	Adjusted opening balances	851,017	-35,610	561,679	0	9,908	1,386,994	680	1,387,674
5.04	Capital transactions with partners	0	-22,179	0	-22,779	0	-44,958	0	-44,958
5.04.04	Treasury shares acquired	0	-22,179	0	0	0	-22,179	0	-22,179
5.04.07	Interest on own capital	0	0	0	-22,779	0	-22,779	0	-22,779
5.05	Total comprehensive income	0	0	0	146,737	-4,126	142,611	-154	142,457
5.05.01	Net income for the period	0	0	0	146,737	0	146,737	-48	146,689
5.05.02	Other comprehensive income	0	0	0	0	-4,126	-4,126	-106	-4,232
5.05.02.04	Translation adjustments in the period	0	0	0	0	578	578	0	578
5.05.02.08	Other comprehensive income	0	0	0	0	-4,636	-4,636	-106	-4,742
5.05.02.09	Other comprehensive income of investees recognized under the equity method	0	0	0	0	-68	-68	0	-68
5.06	Internal changes in shareholders' equity	0	0	0	0	0	0	0	0
5.07	Closing balances	851,017	-57,789	561,679	123,958	5,782	1,484,647	526	1,485,173

**Consolidated financial statements / Statement of added value****(In thousands of reais)**

Code of account	Account description	Accumulated of the	Accumulated of the prior
		current year 01/01/2025–03/31/2025	year 01/01/2024–03/31/2024
7.01	Revenues	593,799	558,236
7.01.01	Sale of goods, products and services	577,312	544,253
7.01.02	Other revenues	13,737	13,871
7.01.02.02	Sales of goods and services	13,737	13,871
7.01.04	Formation/reversal of allowance for doubtful accounts	2,750	112
7.02	Inputs acquired from third parties	-249,294	-262,472
7.02.01	Cost of products, goods and services sold	-211,628	-218,015
7.02.02	Materials, energy, third-party services and other	-4,294	-5,867
7.02.04	Other	-33,372	-38,590
7.02.04.01	Other operating revenues (expenses)	4,587	-3,965
7.02.04.02	Sales expenses	-1,431	-1,972
7.02.04.03	Administrative expenses	-36,528	-32,653
7.03	Gross added value	344,505	295,764
7.04	Retentions	-14,932	-14,345
7.04.01	Depreciation, amortization and depletion	-14,932	-14,345
7.05	Net added value produced	329,573	281,419
7.06	Added value received as transfer	34,029	37,302
7.06.01	Equity in net income of subsidiaries	1,778	1,056
7.06.02	Financial revenues	32,251	36,246
7.07	Total added value payable	363,602	318,721
7.08	Distribution of added value	363,602	318,721
7.08.01	Personnel	55,800	56,543
7.08.01.01	Direct remuneration	43,389	43,480
7.08.01.02	Benefits	9,765	10,366
7.08.01.03	Severance Pay Fund (FGTS)	2,646	2,697
7.08.02	Taxes, duties and contributions	120,172	102,461
7.08.02.01	Federal	109,760	92,987
7.08.02.02	State	100	113
7.08.02.03	Municipal	10,312	9,361
7.08.03	Third-party capital remuneration	18,061	13,028
7.08.03.02	Rentals	980	407
7.08.03.03	Other	17,081	12,621
7.08.04	Remuneration of own capital	169,569	146,689
7.08.04.01	Interest on own capital	24,749	22,779
7.08.04.03	Retained earnings / Loss for the period	144,975	123,958
7.08.04.04	Non-controlling interest in retained earnings	-155	-48

## Performance comment

São Paulo, May 06<sup>th</sup>, 2025

Odontoprev (B3: ODPV3 BZ), Brazil's largest dental plan operator, announces today its consolidated results for the first quarter of 2025 (1Q25).

The information contained in the Quarterly Report (ITR), released to CVM/B3, include the IFRS 17, CPC 50 – Insurance Contracts and IFRS 9/CPC 48 – Financial Instruments were also applied.

The **performance comments** maintain the comparability of data from historical series, since 2006, and are based on standards approved by the National Supplementary Health Agency – ANS.

Below are the conciliation tables from the financial statements (Balance Sheet, Income Statement and Cash Flow) for IFRS 17 and calculating solvency.

## Performance comment

### Balance sheet

(in thousand reais)

	Consolidated		
	Balance at March 31, 2025 (ANSGAAP)	Effects (CPC 50/IFRS 17)	Balance at March 31, 2025 (CPC 50/IFRS 17)
<b>ASSETS</b>			
<b>Current assets</b>	<b>720,891</b>	<b>(101,951)</b>	<b>618,940</b>
Cash and cash equivalents	21,617	-	21,617
Interest earning bank deposits	476,273	-	476,273
Accounts receivable	141,205	(63,630)	77,575
Cash considerations/ Premiums receivable	95,729	(95,729)	-
Provision for credit losses	(24,164)	24,164	-
Participation of beneficiaries in indemnifying events/claims	1,379	(1,379)	-
Healthcare plan operators	8,722	(8,722)	-
Other receivables from operations with healthcare plans	18,921	(18,921)	-
Assets of insurance and reinsurance contracts	-	29,836	29,836
Other accounts receivable	40,618	7,121	47,739
Inventory	6	-	6
Recoverable taxes	30,896	-	30,896
Prepaid expenses	5,963	-	5,963
Other current assets	44,931	(38,321)	6,610
<b>Non-current assets</b>	<b>1,601,170</b>	<b>15,793</b>	<b>1,616,963</b>
Interest earning bank deposits valued at amortized cost	538,771	-	538,771
Deferred income tax and social contribution	-	15,445	15,445
Other non-current assets	83,987	-	83,987
Investments (ownership interest under the equity method)	6,016	348	6,364
Property, plant and equipment	50,354	-	50,354
Intangible assets	922,042	-	922,042
<b>TOTAL ASSETS</b>	<b>2,322,061</b>	<b>(86,158)</b>	<b>2,235,903</b>

	Consolidated		
	Balance at March 31, 2025 (ANSGAAP)	Effects (CPC 50/IFRS 17)	Balance at March 31, 2025 (CPC 50/IFRS 17)
<b>LIABILITIES</b>			
<b>Current assets</b>	<b>749,738</b>	<b>(18,989)</b>	<b>730,749</b>
Technical reserves for health care operations	296,777	(296,777)	-
Liabilities of insurance and reinsurance contracts	-	274,164	274,164
Debits from health care operations	21,028	(1,123)	19,905
Taxes and charges payable	34,383	-	34,383
Sundry debits	397,550	4,747	402,297
<b>Non-current assets</b>	<b>153,085</b>	<b>(12,704)</b>	<b>140,381</b>
Provision for lawsuits (Contingencies)	78,155	-	78,155
Taxes and social security charges payable	12,998	(12,704)	294
Sundry debits	61,932	-	61,932
<b>Shareholders' equity</b>	<b>1,419,238</b>	<b>(54,465)</b>	<b>1,364,773</b>
Realized capital	851,017	-	851,017
Capital reserves	(35,610)	-	(35,610)
Legal reserve	127,428	-	127,428
Tax incentive reserve	129	-	129
Proposed addition dividend	81,000	-	81,000
Treasury shares	(79,436)	-	(79,436)
Investment and expansion statutory reserve	331,605	(47,872)	283,733
Retained earnings and losses	141,883	3,092	144,975
Equity valuation adjustments	(801)	-	(801)
Accumulated translation adjustments	1,714	324	2,038
Other comprehensive income	-	(10,009)	(10,009)
Non-controlling interest	309	-	309
<b>TOTAL LIABILITIES</b>	<b>2,322,061</b>	<b>(86,158)</b>	<b>2,235,903</b>

## Performance comment

### Statement of income

(in thousands of reais)

			Consolidated
	Balance at March 31, 2025 (ANSGAAP)	Effects (CPC 50/IFRS 17)	Balance at March 31, 2025 (CPC 50/IFRS 17)
Net considerations/Retained premiums	582,548	(582,548)	-
Insurance	7,051	(7,051)	-
Insurance revenue (PAA)	-	447,979	447,979
Insurance revenue (BBA)	-	129,333	129,333
<b>INSURANCE AND REINSURANCE REVENUES</b>	<b>589,599</b>	<b>(12,287)</b>	<b>577,312</b>
Net indemnifiable events/retained claims	(165,448)	165,448	-
Changes in provision for events/claims incurred but Not Reported (IBNR)	5,401	(5,401)	-
Claims	(2,340)	2,340	-
Claims technical Reserves	229	(229)	-
Sales expenses	(58,759)	57,328	(1,431)
Direct taxes from operations with health care plans for the operator	(28,558)	28,558	-
Dental materials	(3,802)	3,802	-
Other operating costs	(20,791)	20,791	-
Insurance expenses	-	(332,100)	(332,100)
<b>INSURANCE AND REINSURANCE EXPENSES</b>	<b>(274,068)</b>	<b>(59,463)</b>	<b>(333,531)</b>
<b>INCOME (LOSS) FROM INSURANCE AND REINSURANCE OPERATIONS</b>	<b>315,531</b>	<b>(71,750)</b>	<b>243,781</b>
Sales of goods and services	13,737	-	13,737
Taxes on sales of goods and services	(3,249)	-	(3,249)
Provision for credit losses	(7,155)	9,905	2,750
Other operating revenues (expenses)	957	8,698	9,655
<b>GROSS INCOME</b>	<b>319,821</b>	<b>(53,147)</b>	<b>266,674</b>
Administrative expenses	(94,889)	64,757	(30,132)
Long-term incentive program (ILP)	(4,241)	3,784	(457)
Profit sharing	(6,220)	-	(6,220)
Net financial income (loss)	25,923	(10,753)	15,170
Financial revenues	32,251	-	32,251
Financial expenses	(6,328)	(10,753)	(17,081)
Financial expenses	(6,328)	(10,753)	(17,081)
Equity in net income of subsidiaries	1,650	128	1,778
<b>INCOME (LOSS) BEFORE INCOME TAXES</b>	<b>242,044</b>	<b>4,769</b>	<b>246,813</b>
Income tax and social contribution	(75,567)	(1,677)	(77,244)
<b>NET INCOME FOR THE YEAR</b>	<b>166,477</b>	<b>3,092</b>	<b>169,569</b>
Attributable to:			
Company's shareholders	166,632	3,092	169,724
Non-controlling interest	(155)	-	(155)
<b>NET INCOME FOR THE YEAR</b>	<b>166,477</b>	<b>3,092</b>	<b>169,569</b>

## Performance comment

### Statement of cash flow

(in thousands of reais)

	Consolidated		
	Balance at March 31, 2025 (ANSGAAP)	Effects (CPC 50/IFRS 17)	Balance at March 31, 2025 (CPC 50/IFRS 17)
<b>Net cash from operating activities</b>	<b>53,469</b>	-	<b>53,469</b>
<b>Cash generated in operations</b>	<b>261,644</b>	<b>(1,415)</b>	<b>260,229</b>
Net income (loss) for the period	166,477	3,092	169,569
Depreciation and amortization	14,932	-	14,932
Net inflation adjustments	1,006	-	1,006
Provision for lawsuits	953	-	953
Disposal of non-current assets and other	1,053	-	1,053
Equity in net income of subsidiaries	(1,650)	(128)	(1,778)
Provision for credit losses	7,155	(9,905)	(2,750)
Changes in provision for events/claims incurred but Not Reported (PEONA)	(5,401)	5,401	-
Income tax and social contribution	75,567	1,677	77,244
Provision for unearned premiums (UP)/considerations	1,781	(1,781)	-
Changes in technical claims reserves	(229)	229	-
<b>Changes in assets and liabilities</b>	<b>(208,175)</b>	<b>1,415</b>	<b>(206,760)</b>
Interest earning bank deposits (Financial assets at fair value through profit or loss)	(114,479)	-	(114,479)
Receivables from operations with healthcare plans (clients)	229	(229)	-
Other accounts receivable, recoverable taxes and prepaid expenses and other current assets	(25,932)	17,126	(8,806)
Inventories	50	-	50
Long-term assets (Non-current)	207	-	207
Provision for Unsettled claims (UC)	720	(720)	-
Assets and liabilities of insurance and reinsurance contracts	-	(18,874)	(18,874)
Tax obligations (taxes payable)	(2,269)	(512)	(2,781)
Labor obligations, Suppliers, Advance from clients and Other accounts payable (Sundry debits)	(4,670)	1,695	(2,975)
Non-current liabilities	5,671	-	5,671
Income tax and social contribution paid	(70,925)	-	(70,925)
Trading on operations	6,720	(13)	6,707
Other technical reserves (OTHER)	(2,942)	2,942	-
Interest paid	(555)	-	(555)
<b>Net cash from investment activities</b>	<b>(16,740)</b>	-	<b>(16,740)</b>
Acquisition of Fixed assets	(444)	-	(444)
Acquisition of Intangibles assets	(14,178)	-	(14,178)
Dividends received from Subsidiaries and jointly-controlled subsidiaries	1,575	-	1,575
Interest earning bank deposits (Financial assets valued at amortized cost)	(3,693)	-	(3,693)
<b>Net cash from financing activities</b>	<b>(31,643)</b>	-	<b>(31,643)</b>
Dividends and Interest on capital paid	(21,642)	-	(21,642)
Acquisition of Treasury shares	(7,864)	-	(7,864)
Rent payments	(2,137)	-	(2,137)
<b>Increase (decrease) in cash and cash equivalents</b>	<b>5,086</b>	-	<b>5,086</b>
Opening balance of cash and cash equivalents	16,531	-	16,531
Closing balance of cash and cash equivalents	21,617	-	21,617



## Performance comment

**ANS establishes the rules for recognizing technical provisions and criteria for maintaining minimum shareholders' equity in accordance with RN 569/2022. As of 2023, the regulatory capital assessment must consider the highest of the following values: (i) base capital; and (ii) risk-based capital.**

The risk-based regulatory capital model considers five risk categories, namely:

(a) Underwriting risk is the uncertainty measure related to an adverse economic position that goes against the operator's expectations at the time of preparing its underwriting policy regarding the uncertainties existing in the estimation of technical provisions and those related to pricing.

(b) Credit risk is the measure of uncertainty related to the probability of the counterparty to a transaction, or a debt issuer, not honoring, total or partially, its financial commitments, or having its credit risk classification changed.

(c) Operational risk is the measure of uncertainty that understands the risks related to internal procedures (loss resulting from inadequacies or failures in internal processes, people and systems).

(d) Legal risk is the measure of uncertainty related to the lack of a complete legal foundation; is the risk of non-compliance with applicable laws, rules, regulations, agreements, current practices or ethical standards, including the risk that the nature of the product/service provided may make the operator particularly vulnerable to litigation.

(e) Market risk is the measure of uncertainty related to exposure to losses arising from the volatility of asset prices, such as share prices, interest rates, exchange rates, commodity prices and property prices.

## Performance comment

The required sufficiency went from R\$43 million on December 31, 2024, to R\$151 million on March 31, 2025.

	March 31, 2025	December 31, 2024
Reference capital	11,702	11,702
(x) K factor <sup>1</sup>	3.23%	3.23%
<b>Adjusted minimum shareholders' equity (PMA)</b>	<b>378</b>	<b>378</b>
Shareholders' equity	1,418,929	1,285,651
Ownership interest in regulated entities	(4,225)	(4,166)
Deferred acquisition costs	(38,321)	(22,604)
Prepaid expenses	(5,254)	(7,571)
Intangible assets	(899,598)	(897,398)
Goodwill from indirect interests	(14,532)	(14,532)
<b>Adjusted shareholders' equity (PLA)</b>	<b>456,999</b>	<b>339,380</b>
<b>Risk-based capital (CBR)<sup>2</sup></b>	<b>306,392</b>	<b>296,780</b>
<b>Required sufficiency</b>	<b>150,607</b>	<b>42,600</b>

<sup>1</sup> Factor K corresponds to the classification: group dentistry, tertiary segment and region 1 as per appendix RN 569/2022;

<sup>2</sup> The CBR value takes into account the use of the reduced factors, as defined in article 6 of NR 569/2022.

## Performance comment



## Key metrics

(R\$000, except otherwise specified)	1Q25	1Q24	Δ%	4Q24	Δ%	APR24- MAR25	APR23- MAR24	Δ%
Net operating revenue (NOR)	590,466	550,696	7.2	589,642	0.1	2,309,557	2,169,584	6.5
Average ticket (R\$/member/month)	22.49	21.42	5.0	22.41	0.4	22.26	21.59	3.1
Number of members	8,900,512	8,634,125	3.1	8,924,269	(0.3)	8,900,512	8,634,125	3.1
Organic net additions (members)	(23,757)	16,232	-	105,979	-	266,387	369,541	(27.9)
Cost of services	211,263	192,062	10.0	235,891	(10.4)	890,638	862,553	3.3
Average Cost of services (R\$/member/month)	7.90	7.42	6.5	8.86	(10.9)	8.47	8.51	(0.5)
Gross Profit (ex-IBNR)	379,203	358,634	5.7	353,751	7.2	1,418,919	1,307,031	8.6
Dental care ratio (%)	35.8	34.9	0.9 p.p.	40.0	(4.2 p.p.)	38.6	39.8	(1.2 p.p.)
Selling expenses (%)	10.0	11.0	(1.0 p.p.)	12.1	(2.1 p.p.)	11.2	10.5	0.7 p.p.
G&A (%)	13.5	13.7	(0.2 p.p.)	18.0	(4.5 p.p.)	15.2	15.7	(0.5 p.p.)
SG&A (%)	23.5	24.7	(1.2 p.p.)	30.1	(6.6 p.p.)	26.4	26.1	0.3 p.p.
Combined ratio (%)	59.3	59.6	(0.3 p.p.)	70.1	(10.9 p.p.)	65.0	65.9	(0.9 p.p.)
Bad debt (%)	1.2	1.9	(0.7 p.p.)	2.2	(1.0 p.p.)	2.1	2.2	(0.1 p.p.)
Adjusted EBITDA	226,052	202,464	11.7	153,309	47.4	717,982	647,811	10.8
Adjusted EBITDA margin (%)	38.3	36.8	1.5 p.p.	26.0	12.3 p.p.	31.1	29.9	1.2 p.p.
Net financial income	25,938	29,224	(11.2)	28,012	(7.4)	106,522	88,191	20.8
Net income	166,632	155,385	7.2	114,022	46.1	544,828	522,301	4.3
(-) Non-recurring events	-	4,572	-	-	-	-	46,089	-
Recurring Net income	166,632	150,813	10.5	114,022	46.1	544,828	476,212	14.4
Total Capital (thousand)	552,496	552,496	-	552,496	-	552,496	552,496	-
Number of Treasury shares (thousand)	6,930	1,855	273.7	6,189	12.0	6,930	1,855	273.7
Outstanding shares	545,565	550,641	(0.9)	546,307	(0.1)	545,565	550,641*	(0.9)
Recurring EPS (R\$/ share)	0.305	0.274	11.5	0.209	46.3	0.999	0.865	15.5
Dividends	118,000	73,000	61.6	81,000	45.7	407,905	500,254	(18.5)
IOC	24,749	22,779	8.6	21,423	15.5	86,207	84,014	2.6
Share buyback	7,864	44,435	(82.3)	11,903	(33.9)	35,000	44,435	(21.2)
Total Shareholder Remuneration	150,613	140,214	7.4	114,326	31.7	529,112	628,703	(15.8)
Payout (%)	90.4	90.2	-	100.3	-	-	-	-
Capex	14,617	13,743	6.4	29,303	(50.1)	94,627	81,884	15.6
Net cash	1,036,661	1,179,926	(12.1)	913,403	13.5	1,036,661	1,179,926	(12.1)
Required sufficiency	150,606	319,418	(52.8)	42,606	253.5	150,606	319,418	(52.8)
ROE	-	-	-	-	-	42.1	42.4	(0.3 p.p.)

\*Includes 2023 Dividend of R\$427 million approved at AGM in April 2024

## Performance comment



## Key Metrics per segment

Key metrics	Corporate							
	1Q25	1Q24	Δ%	4Q24	Δ%	APR24-MAR25	APR23-MAR24	Δ%
Net operating revenue (NOR)	328,632	300,928	9.2	326,966	0.5	1,287,362	1,186,826	8.5
Average ticket	18.06	17.10	5.6	17.95	0.6	18.00	17.15	4.9
Number of members (000)	6,300	6,104	3.2	6,359	(0.9)	6,300	6,104	3.2
Net additions (000)	(59)	(3)	-	98	-	195	241	-
Cost of services	151,428	133,624	13.3	169,138	(10.5)	636,224	607,362	4.8
Dental care ratio (%)	46.1	44.4	1.7 p.p.	51.7	(5.6 p.p.)	49.4	51.2	(1.8 p.p.)
Cost of services / member / month	7.98	7.29	9.3	8.94	(10.7)	8.55	8.46	1.1
Gross profit	177,204	167,304	5.9	157,828	12.3	651,139	579,464	12.4
Gross margin (%)	53.9	55.6	(1.7 p.p.)	48.3	5.6 p.p.	50.6	48.8	1.8 p.p.
Selling expenses	20,775	21,625	(3.9)	25,445	(18.4)	91,862	82,549	11.3
Selling expenses (%)	6.3	7.2	(0.9 p.p.)	7.8	(1.5 p.p.)	7.1	7.0	0.1 p.p.
Contribution Margin	156,429	145,679	7.4	132,383	18.2	559,277	496,916	12.5
Contribution Margin (% NOR)	47.6	48.4	(0.8 p.p.)	40.5	7.1 p.p.	43.4	41.9	1.5 p.p.

Key metrics	SME							
	1Q25	1Q24	Δ%	4Q24	Δ%	APR24-MAR25	APR23-MAR24	Δ%
Net operating revenue (NOR)	122,600	112,825	8.7	124,352	(1.4)	478,270	439,921	8.7
Average ticket	26.52	25.47	4.1	27.22	(2.6)	26.19	26.12	0.3
Number of members (000)	1,646	1,564	5.3	1,609	2.4	1,646	1,564	5.3
Net additions (000)	38	13	-	8	-	82	170	-
Cost of services	29,127	27,136	7.3	32,613	(10.7)	123,674	123,820	(0.1)
Dental care ratio (%)	23.8	24.1	(0.3 p.p.)	26.2	(2.4 p.p.)	25.9	28.1	(2.2 p.p.)
Cost of services / member / month	5.97	5.81	2.7	6.78	(11.9)	6.42	6.98	(8.0)
Gross profit	93,473	85,689	9.1	91,740	1.9	354,596	316,101	12.2
Gross margin (%)	76.2	75.9	0.3 p.p.	73.8	2.4 p.p.	74.1	71.9	2.2 p.p.
Selling expenses	14,777	13,593	8.7	16,867	(12.4)	62,643	52,458	19.4
Selling expenses (%)	12.1	12.0	0.1 p.p.	13.6	(1.5 p.p.)	13.1	11.9	1.2 p.p.
Contribution Margin	78,696	72,096	9.2	74,872	5.1	291,953	263,643	10.7
Contribution Margin (% NOR)	64.2	63.9	0.3 p.p.	60.2	4.0 p.p.	61.0	59.9	1.1 p.p.

Key metrics	Individual plans							
	1Q25	1Q24	Δ%	4Q24	Δ%	APR24-MAR25	APR23-MAR24	Δ%
Net operating revenue (NOR)	121,513	115,146	5.5	118,700	2.4	469,628	465,173	1.0
Average ticket	44.97	42.33	6.3	43.72	2.9	43.21	41.70	3.6
Number of members (000)	954	965	(1.2)	957	(0.3)	954	965	(1.2)
Net additions (000)	(3)	7	-	(0)	-	(11)	(41)	-
Cost of services	21,915	22,279	(1.6)	24,734	(11.4)	96,216	107,025	(10.1)
Dental care ratio (%)	18.0	19.3	(1.3 p.p.)	20.8	(2.8 p.p.)	20.5	23.0	(2.5 p.p.)
Cost of services / member / month	7.64	7.72	(1.0)	8.61	(11.3)	8.35	9.04	(7.6)
Gross profit	99,597	92,868	7.2	93,966	6.0	373,411	358,148	4.3
Gross margin (%)	82.0	80.7	1.3 p.p.	79.2	2.8 p.p.	79.5	77.0	2.5 p.p.
Selling expenses	22,500	23,654	(4.9)	27,932	(19.4)	100,621	89,580	12.3
Selling expenses (%)	18.5	20.5	(2.0 p.p.)	23.5	(5.0 p.p.)	21.4	19.3	2.1 p.p.
Contribution Margin	77,097	69,214	11.4	66,034	16.8	272,791	268,568	1.6
Contribution Margin (% NOR)	63.4	60.1	3.3 p.p.	55.6	7.8 p.p.	58.1	57.7	0.4 p.p.

\*Excludes the free choice plans provisions/ reversal

## Performance comment



### ESG Metrics



In April 2025, Odontoprev published its Annual Sustainability Report 2024, based on the GRI (Global Reporting Initiative), SASB (Sustainability Accounting Standards Board) and TCFD (Task Force on Climate-related Financial Disclosures) guidelines. To access the report, [click here](#).

Odontoprev became part of B3's Corporate Sustainability Index (ISE) since May 5th. The index comprises 82 companies from 40 sectors.

## ISEB3

Environmental key indicators	1Q24	1Q25
Total consumption of electricity (kWh) [GRI-302]	273,817	577,354
Total consumption of water (m³) [GRI-303]	612	633
Greenhouse gas emissions per scope (tCO2e) [GRI 305]	98	116
Scope 1 - direct emissions (tCO2e)	0	2
Scope 2 - indirect emissions related to purchase of energy (tCO2e)	13	26
Scope 3 - indirect emissions from the value chain (tCO2e)	85	88
Waste Management[GRI 306]	57	119
Paper disposal (Kg)	51	107
Plastic disposal (Kg)	4	8
Aluminium disposal (Kg)	1	2
Glass disposal (Kg)	1	1
Personnel key indicators	1Q24	1Q25
Total employees (a)	1,936	1,927
Board of Directors & Fiscal Council Members (b)	11	11
Total employees ex Board members (a) - (b)	1,925	1,916
Call Center employees	170	168
Total turnover	6.9%	6.5%
Turnover without Call Center	6.3%	6.4%
Call Center turnover	14.1%	14.3%
[GRI G4-LA12]		
Gender distribution		
% Men	28.3%	27.0%
% Women	71.7%	73.0%
% Women at Strategic Management	44.6%	33.3%
[GRI G4-LA12]		
Functional distribution		
Statutory	0.4%	0.4%
Management/Superintendence	4.5%	4.4%
Supervisory	5.1%	5.5%
Administrative	32.2%	33.5%
Operational	53.8%	52.6%
Apprentice/Interns	4.2%	3.7%
[GRI G4-LA12]		
Age distribution		
< 21 years	4.2%	4.2%
21 - 29 years	23.6%	23.3%
30 - 39 years	35.8%	34.7%
40 - 49 years	24.5%	24.8%
> 50 years	11.9%	13.0%

## Performance comment



## Operational and financial performance


## Net operating revenue (NOR)

Net operating revenue (NOR)													
	1Q25		1Q24		Δ%	4Q24		Δ%	APR24-MAR25		APR23-MAR24		Δ%
	R\$ 000	% NOR	R\$ 000	% NOR		R\$ 000	% NOR		R\$ 000	% NOR	R\$ 000	% NOR	
(+) Payments, net	601,302	101.8	554,423	100.7	8.5	596,396	101.1	0.8	2,342,125	101.4	2,188,973	100.9	7.0
(+) Sales of services and products	13,737	2.3	13,871	2.5	(1.0)	12,255	2.1	12.1	52,531	2.3	54,370	2.5	(3.4)
(+) Odontored (México)	7,234	1.2	11,549	2.1	(37.4)	10,950	1.9	(33.9)	35,870	1.6	39,145	1.8	(8.4)
<b>Gross operating revenue (GOR)</b>	<b>622,273</b>	<b>105.4</b>	<b>579,843</b>	<b>105.3</b>	<b>7.3</b>	<b>619,601</b>	<b>105.1</b>	<b>0.4</b>	<b>2,430,526</b>	<b>105.2</b>	<b>2,282,488</b>	<b>105.2</b>	<b>6.5</b>
(-) Direct taxes on dental care operations	28,558	4.8	25,524	4.6	11.9	26,378	4.5	8.3	106,864	4.6	97,055	4.5	10.1
(-) Taxes on sales of services and products	3,249	0.6	3,623	0.7	(10.3)	3,581	0.6	(9.3)	14,105	0.6	15,849	0.7	(11.0)
<b>Net operating revenue (NOR)</b>	<b>590,466</b>	<b>100.0</b>	<b>550,696</b>	<b>100.0</b>	<b>7.2</b>	<b>589,642</b>	<b>100.0</b>	<b>0.1</b>	<b>2,309,557</b>	<b>100.0</b>	<b>2,169,584</b>	<b>100.0</b>	<b>6.5</b>

The consolidated net revenue (NOR) reached **R\$590,466 in 1Q25, up 7.2% YoY, with a higher average ticket in all segments.** Over the last twelve months, NOR was R\$2,309,557, up 6.5% Y/Y.

## Net revenue

R\$ million



## Consolidated Average Ticket

The consolidated average ticket in 1Q25 was R\$22.49, **5.0% higher** than the R\$21.42 registered in 1Q24.

	1Q25	1Q24	Δ%	4Q24	Δ%	APR24-MAR25	APR23-MAR24	Δ%
Payments, net R\$000 (A)	601,302	554,423	8.5	596,396	0.8	2,342,125	2,188,973	7.0
Average number of members (B)	8,912,391	8,626,009	3.3	8,871,280	0.5	8,767,319	8,449,355	3.8
<b>Average ticket (R\$/member/month) (A/B)/# of months</b>	<b>22.49</b>	<b>21.42</b>	<b>5.0</b>	<b>22.41</b>	<b>0.4</b>	<b>22.26</b>	<b>21.59</b>	<b>3.1</b>

## Performance comment



### Total number of members

Odontoprev registered 8,900,512 members in 1Q25, with a net loss of 24 thousand beneficiaries in the quarter, and a net addition of 266 thousand in the last twelve months.


Historically, the dental sector commercial activities in Q1 are slower than in the other quarters.

The corporate segment presented a net loss of 59 thousand lives in 1Q25, and a net addition of 195 thousand new clients in the last twelve months.

The non-corporate segments showed a net addition of 35 thousand lives in the quarter, of which 38 thousand from the Bradesco channel.

### Bradesco Dental: SME net additions in first quarters

Thousand lives



Bradesco Dental has been the best-selling brand over the last years, representing today 51% of the total portfolio, especially in the Small and Medium-sized companies segment, which recorded a net addition of 34 thousand lives in 1Q25, reinforcing our strategic positioning.

	Portfolio 1Q25	% segment	Net additions		Portfolio 1Q24	% segment	Net additions	
			1Q25	APR24- MAR25			1Q24	APR23- MAR24
<b>Total</b>	<b>8,900,512</b>	<b>100.0%</b>	<b>(23,757)</b>	<b>266,387</b>	<b>8,634,125</b>	<b>100.0%</b>	<b>16,232</b>	<b>369,541</b>
bradesco dental	4,560,899	51.2%	(9,399)	300,047	4,260,852	49.3%	(25,554)	190,274
Others <sup>1</sup>	4,339,613	48.8%	(14,358)	(33,660)	4,373,273	50.7%	41,786	179,267
<b>Corporate</b>	<b>6,299,893</b>	<b>100.0%</b>	<b>(58,727)</b>	<b>195,397</b>	<b>6,104,496</b>	<b>100.0%</b>	<b>(3,348)</b>	<b>241,035</b>
bradesco dental	2,805,306	44.5%	(47,325)	157,723	2,647,583	43.4%	(51,709)	95,604
Others <sup>1</sup>	3,494,587	55.5%	(11,402)	37,674	3,456,913	56.6%	48,361	145,431
<b>SME</b>	<b>1,646,333</b>	<b>100.0%</b>	<b>37,829</b>	<b>82,171</b>	<b>1,564,162</b>	<b>100.0%</b>	<b>12,896</b>	<b>169,795</b>
bradesco dental	1,325,045	80.5%	34,483	156,679	1,168,366	74.7%	15,059	98,190
Others <sup>1</sup>	321,288	19.5%	3,346	(74,508)	395,796	25.3%	(2,163)	71,605
<b>Individual Plans</b>	<b>954,286</b>	<b>100.0%</b>	<b>(2,859)</b>	<b>(11,181)</b>	<b>965,467</b>	<b>100.0%</b>	<b>6,684</b>	<b>(41,289)</b>
bradesco dental	430,548	45.1%	3,443	(14,355)	444,903	46.1%	11,096	(3,520)
Others <sup>1</sup>	523,738	54.9%	(6,302)	3,174	520,564	53.9%	(4,412)	(37,769)

<sup>1</sup>On Corporate and SME, includes Odontoprev, Odonto System, Mogidonto and BrasilDental. On Individual Plans, also includes retail channels.

## Performance comment



### Cost of services and dental care ratio

	1Q25		1Q24		Δ% p.p. NOR	4Q24		Δ% p.p. NOR	APR24-MAR25		APR23-MAR24		Δ% p.p. NOR
	R\$ 000	% NOR	R\$ 000	% NOR		R\$ 000	% NOR		R\$mil	% NOR	R\$ 000	% NOR	
Cost of services (ex IBNR)	211,263	35.8	192,062	34.9	0.9	235,891	40.0	(4.2)	890,638	38.6	862,553	39.8	(1.2)
Indemnifiable claims, net	184,203	31.2	166,634	30.3	0.9	201,256	34.1	(2.9)	775,677	33.6	775,146	35.7	(2.1)
Dental materials	4,117	0.7	4,819	0.9	(0.2)	12,891	2.2	(1.5)	25,570	1.1	18,705	0.9	0.2
Other operational costs and Provisions/reversals	20,604	3.5	18,016	3.3	0.2	18,978	3.2	0.3	78,739	3.4	59,860	2.8	0.6
Odontored (México)	2,340	0.4	2,593	0.5	(0.1)	2,765	0.5	(0.1)	10,652	0.5	8,842	0.4	0.1


For comparison purposes, the IBNR Provision (Incurred but not Reported) and technical reserves (Odontored), were excluded from the Cost of Services.

In 1Q25, the dental care ratio was 35.8%, +0.9 p.p. YoY, with a drop in the SME and individual plan segments. In the last twelve months, the cost of services represented 38.6% of NOR, more efficient in relation to the previous period, with improvements from all business segments.

Dental loss ratio (% NOR)	1Q25	1Q24	Δ p.p.	APR24-MAR25	APR23-MAR24	Δ p.p.
Corporate	46.1	44.4	1.7	49.4	51.2	(1.8)
SME	23.8	24.1	(0.3)	25.9	28.1	(2.2)
Individual	18.0	19.3	(1.3)	20.5	23.0	(2.5)
<b>Consolidated</b>	<b>35.8</b>	<b>34.9</b>	<b>0.9</b>	<b>38.6</b>	<b>39.8</b>	<b>(1.2)</b>

### Cost of Services

R\$ million and % NOR



Dental care ratio %	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	APR24 MAR25
<b>Corporate</b>	50.2	51.4	56.3	52.5	50.7	50.9	42.1	46.5	49.9	51.4	49.1	49.4
Average	50.5%				49.3%							
<b>SME</b>	39.0	40.6	45.5	42.4	40.2	37.9	28.4	28.5	26.9	28.3	26.0	25.9
Average	38.4%				27.0%							
<b>Individual Plans*</b>	28.3	25.6	25.2	27.5	30.0	35.6	40.9	34.9	28.1	23.3	20.8	20.5
Average	32.1%				25.5%							
<b>Consolidated</b>	46.2	46.6	49.1	45.7	44.1	44.5	40.6	39.3	40.2	39.6	38.4	38.6
Average	45.0%				39.2%							

\*Excludes the free choice plans provisions/ reversal




Performance comment



The three business segments have a similar average cost of services. On the other hand, the pricing of non-corporate products, in particular Individual plans, assumes conservative parameters related to adverse selection, contract cancellation and bad debt.

Consolidated average ticket and cost of services per member per month

R\$ / member / month



Individual Plans

+6.3%

42.2 42.3 42.4 42.0 43.7 45.0

8.9 7.7 9.0 8.3 8.6 7.6

4Q23 1Q24 2Q24 3Q24 4Q24 1Q25


Performance comment



Selling expenses

	1Q25	1Q24	Δ%	4Q24	Δ%	APR24- MAR25	APR23- MAR24	Δ%
Selling expenses (R\$ 000)	58,759	60,534	(2.9)	71,351	(17.6)	259,566	227,091	14.3
Selling expenses (% NOR)	10.0	11.0	(1.0 p.p.)	12.1	(2.1 p.p.)	11.2	10.5	0.7 p.p.

The selling expenses were 11.2% over the last twelve months, closer to historical levels. In the quarter, there was a drop of 2.9% in relation to 1Q24.



## Performance comment




### Administrative expenses (G&A)

	1Q25		1Q24		Δ%	Δ% p.p. NOR	4Q24		Δ%	Δ% p.p. NOR	APR24-MAR25		APR23-MAR24		Δ%	Δ% p.p. NOR
	R\$ 000	% NOR	R\$ 000	% NOR			R\$ 000	% NOR			R\$mil	% ROL	R\$ 000	% NOR		
Personnel	45,803	7.8	44,011	8.0	4.1	(0.2)	52,358	8.9	(12.5)	(1.1)	189,371	8.2	185,314	8.5	2.2	(0.3)
Third parties services	16,528	2.8	18,501	3.4	(10.7)	(0.6)	22,378	3.8	(26.1)	(1.0)	77,973	3.4	77,357	3.6	0.8	(0.2)
Rentals and post services	9,527	1.6	7,052	1.3	35.1	0.3	18,468	3.1	(48.4)	(1.5)	46,065	2.0	42,885	2.0	7.4	-
Publicity and advertising	3,951	0.7	3,567	0.6	10.8	0.1	12,169	2.1	(67.5)	(1.4)	25,900	1.1	19,880	0.9	30.3	0.2
Taxes and fees	1,967	0.3	922	0.2	113.2	0.1	1,023	0.2	92.3	0.1	5,240	0.2	5,159	0.2	1.6	-
Others	2,068	0.4	1,643	0.3	25.9	0.1	(253)	-	-	0.4	6,280	0.3	9,243	0.4	(32.1)	(0.1)
<b>G&amp;A (adjusted at EBITDA base)</b>	<b>79,844</b>	<b>13.5</b>	<b>75,696</b>	<b>13.7</b>	<b>5.5</b>	<b>(0.2)</b>	<b>106,142</b>	<b>18.0</b>	<b>(24.8)</b>	<b>(4.5)</b>	<b>350,829</b>	<b>15.2</b>	<b>339,839</b>	<b>15.7</b>	<b>3.2</b>	<b>(0.5)</b>
Depreciation and amortization	13,383	2.3	12,678	2.3	5.6	-	13,963	2.4	(4.2)	(0.1)	50,498	2.2	51,293	2.4	(1.5)	(0.2)
Amortization of utilization rights	1,549	0.3	1,667	0.3	(7.1)	-	1,494	0.3	3.7	-	6,240	0.3	7,339	0.3	(15.0)	-
<b>G&amp;A (not adjusted at EBITDA base)</b>	<b>14,932</b>	<b>2.5</b>	<b>14,345</b>	<b>2.6</b>	<b>4.1</b>	<b>(0.1)</b>	<b>15,458</b>	<b>2.6</b>	<b>(3.4)</b>	<b>(0.1)</b>	<b>56,738</b>	<b>2.5</b>	<b>58,631</b>	<b>2.7</b>	<b>(3.2)</b>	<b>(0.2)</b>
<b>Total administrative expenses (G&amp;A)</b>	<b>94,776</b>	<b>16.1</b>	<b>90,041</b>	<b>16.4</b>	<b>5.3</b>	<b>(0.3)</b>	<b>121,600</b>	<b>20.6</b>	<b>(22.1)</b>	<b>(4.5)</b>	<b>407,568</b>	<b>17.6</b>	<b>398,472</b>	<b>18.4</b>	<b>2.3</b>	<b>(0.8)</b>

The administrative expenses (G&A at Adjusted EBITDA basis) were 13.5% of NOR in 1Q25, 0.2 p.p. lower than 1Q24.

#### G&A

R\$ million and % NOR



## Performance comment



## Allowance for doubtful receivables


	1Q25	1Q24	Δ%	4Q24	Δ%	APR24- MAR25	APR23- MAR24	Δ%
Allowance for doubtful receivables (R\$ 000)	7,155	10,302	(30.5)	13,041	(45.1)	48,894	47,678	2.6
Allowance for doubtful receivables (% NOR)	1.2	1.9	(0.7 p.p.)	3.6	(2.4)	2.1	2.2	(0.1 p.p.)

The allowance for doubtful receivables is calculated considering overdue invoices (60 days for Individual plans and 90 days for corporate plans), plus an average percentage of historical losses.

In 1Q25, the allowance for doubtful receivables was 1.2% of NOR, -0.7 p.p. Y/Y. In the last twelve months, the allowance for doubtful receivables was 2.1% of NOR, the same level observed over the last years.

## Allowance for doubtful receivables

R\$ million and % NOR



## Performance comment




## EBITDA and Adjusted EBITDA

	1Q25		1Q24		Y/Y %	Δ% p.p. NOR	4Q24		Q/Q %	Δ% p.p. NOR	APR24-MAR25		APR23-MAR24		Y/Y %	Δ% p.p. NOR
	R\$ 000	% NOR	R\$ 000	% NOR			R\$ 000	% NOR			R\$ 000	% NOR	R\$ 000	% NOR		
Net Income	166,632	28.2	155,385	28.2	7.2	-	114,022	19.3	46.1	8.9	544,828	23.6	522,301	24.1	4.3	(0.5)
(+) Current income and social contribution tax	60,683	10.3	70,270	12.8	(13.6)	(2.5)	64,348	10.9	(5.7)	(0.6)	220,728	9.6	191,287	8.8	15.4	0.8
(+) Deferred income and social contribution tax	14,884	2.5	(2,552)	(0.5)	(683.2)	3.0	(12,599)	(2.1)	(218.1)	4.6	7,971	0.3	13,987	0.6	(43.0)	(0.3)
(-) Financial income	32,215	5.5	33,394	6.1	(3.5)	(0.6)	34,821	5.9	(7.5)	(0.4)	129,258	5.6	113,282	5.2	14.1	0.4
(+) Financial expenses	6,277	1.1	4,169	0.8	50.6	0.3	6,810	1.2	(7.8)	(0.1)	22,736	1.0	25,091	1.2	(9.4)	(0.2)
(-) Participation of minority shareholders	155	-	48	-	219.5	-	44	-	250.3	-	218	-	(202)	-	(207.5)	-
(+) Depreciation and amortization	13,383	2.3	12,678	2.3	5.6	-	13,963	2.4	(4.2)	(0.1)	50,498	2.2	51,293	2.4	(1.5)	(0.2)
(+) Amortization of utilization rights	1,549	0.3	1,667	0.3	(7.1)	-	1,494	0.3	3.7	-	6,240	0.3	7,339	0.3	(15.0)	-
(-) Equity in subsidiaries	1,651	0.3	1,276	0.2	29.3	0.1	1,726	0.3	(4.4)	-	6,371	0.3	2,744	0.1	132.2	0.2
<b>EBITDA</b>	<b>229,388</b>	<b>38.8</b>	<b>206,899</b>	<b>37.6</b>	<b>10.9</b>	<b>1.2</b>	<b>151,447</b>	<b>25.7</b>	<b>51.5</b>	<b>13.1</b>	<b>717,155</b>	<b>31.1</b>	<b>695,474</b>	<b>32.1</b>	<b>3.1</b>	<b>(1.0)</b>
(+) Incurred But Not Reported Provision - IBNR	(5,401)	(0.9)	(1,280)	(0.2)	321.9	(0.7)	(1,567)	(0.3)	244.7	(0.6)	(8,822)	(0.4)	(9,348)	(0.4)	(5.6)	-
(+) Odontored - Technical reserves	(229)	-	(225)	-	1.9	-	939	0.2	(124.4)	(0.2)	494	-	346	-	42.7	-
(+) Brasildental EBITDA Pro Forma	2,295	0.4	1,643	0.3	39.7	0.1	2,490	0.4	(7.8)	-	9,156	0.4	7,430	0.3	23.2	0.1
(-) ISS reversal	-	-	-	-	-	-	-	-	-	-	-	-	(4,794)	(0.2)	(100.0)	0.2
(-) Reversal TSS/ ANS	-	-	-	-	-	-	-	-	-	-	-	-	(41,296)	(1.9)	(100.0)	1.9
<b>Adjusted EBITDA</b>	<b>226,052</b>	<b>38.3</b>	<b>202,464</b>	<b>36.8</b>	<b>11.7</b>	<b>1.5</b>	<b>153,309</b>	<b>26.0</b>	<b>47.4</b>	<b>12.3</b>	<b>717,982</b>	<b>31.1</b>	<b>647,812</b>	<b>29.9</b>	<b>10.8</b>	<b>1.2</b>

Adjusted EBITDA reached R\$226,052 in 1Q25, 11.7% higher than 1Q24, with margin up 1.5 p.p. Y/Y. In the last twelve months, adjusted EBITDA was a **record R\$717,982, with a margin expansion from 29.9% to 31.1%.**

## Adjusted EBITDA

R\$ million and % NOR



## Performance comment



## Financial income


	1Q25		1Q24		Δ%	4Q24		Δ%	APR24-MAR25		APR23-MAR24		Δ%
	R\$ 000	% Sales	R\$ 000	% Sales		R\$ 000	% Sales		R\$ mil	% Sales	R\$ 000	% Sales	
Net financial income	25,938	4.4	29,224	5.3	(11.2)	28,012	7.8	(7.4)	106,522	4.6	88,191	4.1	20.8
(+) Financial income	32,215	5.5	33,394	6.1	(3.5)	34,821	9.6	(7.5)	129,258	5.6	113,282	5.2	14.1
(-) Financial expenses	6,277	1.1	4,169	0.8	50.6	6,810	1.9	(7.8)	22,736	1.0	25,091	1.2	(9.4)

The financial income was R\$32,215 in 1Q25, slightly lower than the R\$33,394 of 1Q24. In financial expenses, there was a monetary restatement by Selic/ CPI (IPCA).

During 2021, the Company's financial portfolio was partially migrated from Current Assets to long-term Treasury bonds, currently representing 67% of total portfolio, of which post-fixed (78%) and pre-fixed (22%), with the same credit risk profile. The new instruments are booked at their yield curve, minimizing the volatility of the consolidated portfolio, and will be held to maturity. The Company does not make use of derivatives.

## Financial income recent evolution

R\$ million



## Performance comment



### Income and social contribution taxes

	1Q25		1Q24		Δ%	4Q24		Δ%	APR24-MAR25		APR23-MAR24		Δ%
	R\$ 000	% Sales	R\$ 000	% Sales		R\$ 000	% Sales		R\$ 000	% Sales	R\$ 000	% Sales	
<b>Taxes<sup>1</sup></b>	<b>75,567</b>	<b>12.8</b>	<b>68,604</b>	<b>12.5</b>	<b>10.1</b>	<b>51,749</b>	<b>8.8</b>	<b>46.0</b>	<b>228,699</b>	<b>9.9</b>	<b>217,841</b>	<b>10.0</b>	<b>5.0</b>
(-) Current income and social contribution taxes	60,683	10.3	71,156	12.9	(14.7)	64,348	10.9	(5.7)	220,728	9.6	203,854	9.4	8.3
(-) Deferred income and social contribution taxes	14,884	2.5	(2,552)	(0.5)	-	(12,599)	(2.1)	-	7,971	0.3	13,987	0.6	(43.0)

<sup>1</sup> Considers income tax and social contribution relating to Odontoprev's accounting result.

### Effective tax rates

Effective tax rates					
(R\$000, except otherwise specified)	1Q25	1Q24	4Q24	APR24-MAR25	APR23-MAR24
<b>Income before taxes and profit sharing</b>	<b>242,044</b>	<b>223,941</b>	<b>165,727</b>	<b>773,309</b>	<b>740,345</b>
<b>Taxes</b>					
(-) Current income and social contribution taxes	60,683	71,156	64,348	220,728	203,854
(-) Deferred income and social contribution taxes	14,884	(2,552)	(12,599)	7,971	13,987
<b>Total taxes</b>	<b>75,567</b>	<b>68,604</b>	<b>51,749</b>	<b>228,699</b>	<b>217,841</b>
<b>Total effective tax rate (%)<sup>1</sup></b>	<b>31.2%</b>	<b>30.6%</b>	<b>31.2%</b>	<b>29.6%</b>	<b>29.4%</b>

<sup>1</sup> Considers to calculate the Total effective tax rate the Odontoprev's accounting result.

### Goodwill

Goodwill balance for future profitability resulting from the acquisition and subsequent incorporation of the company's Mogidonto (R\$5,089) and Rede Dental (R\$1,854) to be excluded from the calculation of taxable income at the rate of 1/60th for each month of the calculation period.

Goodwill amortization schedule from 2025*	
Period	Total amortization R\$000
2025	4,036
2026	2,908
<b>Total</b>	<b>6,944</b>

\*Includes the difference between all amounts paid and the fair value of assets and liabilities of investments acquired and evaluated through a Purchase Price Allocation (PPA) assessment.

## Performance comment



### Net income

	1Q25	1Q24	Δ%	4Q24	Δ%	APR24- MAR25	APR23- MAR24	Δ%
Net income (R\$ 000)	166,632	155,385	7.2	114,022	46.1	544,828	522,301	4.3
(-) Non-recurring events	-	4,572	-	-	-	-	46,089	-
<b>Recurring Net income</b>	<b>166,632</b>	<b>150,813</b>	<b>10.5</b>	<b>114,022</b>	<b>46.1</b>	<b>544,828</b>	<b>476,212</b>	<b>14.4</b>
Outstanding shares	545,565	550,641	(0.9)	546,307	(0.1)	545,565	550,641	(0.9)
<b>Recurring EPS (R\$/share)</b>	<b>0.305</b>	<b>0.274</b>	<b>11.5</b>	<b>0.209</b>	<b>46.3</b>	<b>0.999</b>	<b>0.865</b>	<b>15.5</b>

Recurring net income reached R\$166,632 in 1Q25, 10.5% higher than 1Q24, when there was a reversal with a net effect of R\$4,572 related to a favorable decision in a lawsuit over the payment of INSS (see the [Earnings Release 1Q24](#)). In the last twelve months, recurring Net income was R\$544,828.


Recurring net income per share came up 11.5% in 1Q25 Y/Y, and 15.5% in the last twelve months.

Since 2021, recurring net income has shown a CAGR of 12%.

#### Net Income: recurring and non-recurring

R\$ million and % NOR

■ Recurring Net income ■ Non-recurring





## Performance comment




## Cash flow

(R\$000)	1Q25	1Q24
<b>CASH FLOW FROM OPERATIONAL ACTIVITIES</b>		
<b>Net income for the period</b>	<b>166,477</b>	<b>155,337</b>
Reconciliation of net income with the cash generated by operations	95,167	94,550
<b>NET CASH FROM OPERATIONAL ACTIVITIES</b>	<b>261,644</b>	<b>249,887</b>
Decrease (increase) in operational assets	(25,446)	19,718
Increase (decrease) in operational liabilities	(68,250)	(48,605)
<b>NET CASH PROVIDED BY (USED IN) OPERATIONAL ACTIVITIES</b>	<b>167,948</b>	<b>221,000</b>
<b>CASH FLOW FROM INVESTING ACTIVITIES</b>		
Acquisition of property and equipment	(444)	(397)
System development, software licenses and other	(14,178)	(13,344)
Deferred selling expenses	1,575	1,625
<b>NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES</b>	<b>(13,047)</b>	<b>(12,116)</b>
<b>CASH FLOW FROM FINANCING ACTIVITIES</b>		
Dividends paid	-	(146)
Interest on capital paid	(21,642)	(19,580)
Share repurchased	(7,864)	-
<b>NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES</b>	<b>(31,643)</b>	<b>(21,106)</b>
<b>INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS</b>	<b>123,258</b>	<b>187,778</b>
Cash, Cash Equivalents and short-term investments		
Balance at the beginning of period	913,403	992,149
Balance at the end of period	1,036,661	1,179,927
<b>INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS</b>	<b>123,258</b>	<b>187,778</b>


## Net cash, zero debt

R\$ million



## Cash flow

R\$ million



s IOC and Buyback.

## Performance comment



### CAPEX


The IT development has historically been Odontoprev's largest investment item.

(R\$thousand)	1Q25	1Q24
IT platform, acquisition/license of software	14,178	13,344
Computer equipment	201	99
Dental plan equipment, furniture and utensils	127	46
Installations	113	250
Others	(3)	3
<b>Total Capex</b>	<b>14,617</b>	<b>13,743</b>

The annual CAPEX level reflects investments in the company's digital initiatives. In the last twelve months, investments in technology reached R\$90 million.

### CAPEX: Technology represents the main investment

R\$ million and % NOR



<sup>1</sup> IT platform, acquisition/licence of software and computer equipment

## Performance comment



## Shareholder remuneration

Dividends (DIV), interest on capital (IOC) and capital reduction (CR) - R\$ thousand												
Payment	Approval	Shareholder position	Type	Period	Gross amount R\$	Net amount R\$	Net value per share R\$			Annual total gross amount R\$	Net Income	Payout
							DIV	IOC	Total			
Total paid in 2014:					216,658	211,822	0.347440879	0.051619184	0.399060063	213,582	194,709	110%
Total paid in 2015:					223,205	217,921	0.356336989	0.056787711	0.413124700	220,945	220,946	100%
Total paid in 2016:					185,559	178,759	0.265208801	0.072859879	0.338068680	172,791	215,990	80%
Total paid in 2017:					279,012	271,887	0.436065493	0.076050963	0.512116456	246,668	244,571 <sup>1</sup>	101%
Total paid in 2018:					86,716	78,340	0.058430479	0.089647129	0.148077608	173,357	284,793	61% <sup>2</sup>
Total paid in 2019:					250,712	241,097	0.351910051	0.095206558	0.447116609	199,334	284,762	70%
Total paid in 2020:					270,219	262,006	0.406237632	0.087765775	0.494003407	333,213	361,128	92%
Total paid in 2021:					261,159	251,455	0.372061480	0.104762084	0.476823564	188,506	380,357	96% <sup>3</sup>
Total paid in 2022:					169,778	159,389	0.179075757	0.108277182	0.287352939	249,258	452,171	91% <sup>4</sup>
07/12/2023	04/05/2023	04/20/2023	DIV	4Q22	120,000	120,000	0.217196275	-	0.217196275	509,728	536,554	95%
12/19/2023	03/14/2023	03/17/2023	IOC	1Q23	21,239	18,053	-	0.032675339	0.032675339			
12/19/2023	06/26/2023	06/29/2023	IOC	2Q23	21,111	17,944	-	0.032478425	0.032478425			
12/19/2023	09/19/2023	09/22/2023	IOC	3Q23	20,544	17,462	-	0.031606078	0.031606078			
Total paid in 2023:					182,894	173,460	0.217196275	0.096759842	0.313956117	447,141	533,581	97%
02/16/2024	12/13/2023	12/18/2023	IOC	4Q23	19,580	16,643	-	0.030122765	0.030122765			
08/21/2024	04/03/2024	04/12/2024	DIV	4Q23	200,000	200,000	0.364065058	-	0.364065058			
12/18/2024	04/03/2024	04/12/2024	DIV	4Q23	227,254	227,254	0.413675305	-	0.413675305			
08/21/2024	03/27/2024	04/01/2024	IOC	1Q24	22,779	19,362	-	0.035162942	0.035162942			
12/18/2024	05/07/2024	05/15/2024	DIV	1Q24	73,000	73,000	0.133326134	-	0.133326134			
Total paid in 2024:					542,613	536,259	0.911066497	0.065285707	0.976352204			
01/29/2025	06/17/2024	06/24/2024	IOC	2Q24	21,642	18,396	-	0.033603739	0.033603739			
04/03/2025	08/06/2024	08/23/2024	DIV	2Q24	85,478	85,478	0.156145973	-	0.156145973	447,141	533,581	97%
04/03/2025	09/26/2024	10/01/2024	IOC	3Q24	18,392	15,633	-	0.028557637	0.028557637			
04/03/2025	11/05/2024	11/08/2024	DIV	3Q24	123,427	123,427	0.225673086	-	0.225673086			
Total paid in 2025:					248,939	242,934	0.381819059	0.062161376	0.443980435			
12/10/2025	12/17/2024	12/20/2024	IOC	4Q24	21,423	18,210	-	0.033307343	0.033307343			
12/10/2025	04/01/2025	04/11/2025	DIV	4Q24	81,000	81,000	0.148598445	-	0.148598445			
12/10/2025	03/19/2025	03/24/2025	IOC	1Q25	24,749	21,037	-	0.038559739	0.038559739			
12/10/2025	05/06/2025	05/09/2025	DIV	1Q25	118,000	118,000	0.216476748	-	0.216476748			
Total to be paid in 2025:					245,173	238,247	0.365075193	0.071867082	0.436942275			
Total since the IPO					4,224,590	4,100,310						

<sup>1</sup> Net income does not consider Bradesco Dental and Odontoprev INSS

<sup>2</sup> In 2018, there was the acquisition of Odonto System, concluded on 08/07/18;

<sup>3</sup> In 2021, also includes R\$177 million disbursed in Buyback Program;

<sup>4</sup> In 2022, also includes R\$163 million disbursed in Buyback Program.

## Performance comment



### Share Buyback Program

The Company, from time to time, carries out Share Buyback Programs which, added to the regular payments of interest on equity and dividends, aim to maximize the generation of value for shareholders.

In April 2025, the total number of shares repurchased under the current program reached 7,403,600, at an adjusted average cost of R\$10.47. The program provides for the repurchase of up to 10 million shares, maturing on August 29<sup>th</sup>, 2025.

On April 30<sup>th</sup>, the number of Treasury shares was 732,100, following the cancellation of 6,670,377 shares at the General Meeting on April 1<sup>st</sup>.


Share Buyback Program						
Date	# Repurchased shares (thousand)	Canceled shares (thousand)	Treasury Shares (thousand)	Amount repurchased (R\$ thousand)	Nominal cost per share (R\$)	Adjusted cost per share (R\$)
1Q24	3,816	-	3,816	44,435	11.64	10.23
2Q24	1,253	-	5,069	15,234	12.16	11.34
4Q24	1,121	-	6,189	11,903	10.62	10.33
2024 Total	6,190	-	6,189	71,572	11.56	10.47
1Q25	742	-	6,930	7,864	10.60	10.42
2Q25	472	6,670	732	5,025	10.64	10.50
2025 Total	1,214	6,670	732	12,888	10.62	10.45
Total	7,404	6,670	732	84,460	11.41	10.47

On May 06<sup>th</sup>, 2025, the Board of Directors approved the distribution of dividends for the first quarter of 2025 of R\$118 million which, added to the IOC of R\$25 million and the share buyback of R\$8 million, totals remuneration to shareholders of R\$151 million, 90% of the 1Q25 net income of R\$167 million.

IDIV B3: Odontoprev is now part of the B3 Dividend Index portfolio, in force since May 5.

### Total shareholder remuneration: Dividends + IOC + Share buybacks

R\$ million




## Performance comment



### Capital Markets

Total shareholder return was -3.5% in 1Q25 and -2.4% in the last twelve months, compared to +8.2% and +2.0% for the IBrX, respectively. Odontoprev's average annual return to shareholders has been +15% since the IPO in 2006, versus the IBrX's average annual variation of +8%.

#### Odontoprev total shareholder return since IPO x IBrX



At the end of March 2025, market capitalization reached R\$5.8 billion with an ADTV of R\$11 million in 1Q25.

The number of individual shareholders was 50,554, 18% higher than the 1Q24, with 480 institutional investors, from more than 30 countries.


Odontoprev in Capital Markets	1Q25	1Q24	Δ %
Total number of shareholders	51,034	43,289	17.9
Individual investors	50,554	42,775	18.2
Institutional investors	480	514	(6.6)
Shares (thousand)	552,496	552,496	-
Treasury shares (thousand)	6,930	1,855	273.6
Market Cap (R\$ billion)	5.8	6.7	(14.1)
Share price (R\$)	10.44	12.16	(14.1)
Adjusted share price by dividends and IOC (R\$)	10.44	10.69	(2.4)

Performance comment



Global shareholder structure: investors from more than 30 countries

After cancellation of Treasury shares to be approved at the Meeting of April 1, 2025



Source: Odontoprev; <sup>1</sup>[According to the Notice to the Market of 06.07.24.](#)

## Notes to the financial statements

## Notes to the individual and consolidated, condensed interim financial statements

March 31, 2025 and 2024, and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

## Balance sheet

(In thousands of reais)

	Note	Company		Consolidated			Note	Company		Consolidated	
		03/31/2025	12/31/2024	03/31/2025	12/31/2024			03/31/2025	12/31/2024	03/31/2025	12/31/2024
<b>Assets</b>						<b>Liabilities</b>					
<b>Current assets</b>		<b>547,143</b>	<b>409,557</b>	<b>618,940</b>	<b>490,076</b>	<b>Current liabilities</b>		<b>693,632</b>	<b>725,553</b>	<b>730,749</b>	<b>764,626</b>
Cash and cash equivalents	3	20,321	15,783	21,617	16,531	Liabilities from insurance and reinsurance contracts	12	272,499	297,287	274,164	299,398
Interest earning bank deposits	4	443,876	327,637	476,273	357,791	Social charges and labor legislation obligations		63,876	57,620	77,509	69,765
Measured at fair value through profit or loss		305,218	192,982	337,615	223,136	Suppliers of goods and services		11,247	11,495	15,839	16,386
Valued at amortized cost		138,658	134,655	138,658	134,655	Debts from health care operations		19,838	12,791	19,905	12,848
Assets of insurance and reinsurance contracts	12	25,823	25,501	29,836	33,316	Anticipated revenue from consideration/premiums		6,732	7,127	6,732	7,127
Other accounts receivable	6	28,351	25,701	47,739	51,749	Taxes and contributions payable	13	28,746	39,986	34,383	47,600
Inventories		-	-	6	56	Dividends and interest on own capital payable		263,875	261,213	263,875	261,213
Recoverable taxes	5	23,518	7,364	30,896	15,853	Lease liabilities	16	1,984	1,958	7,027	6,775
Assets held for sale		-	-	6,610	6,090	Other accounts payable	14	24,835	36,076	31,315	43,514
Prepaid expenses		5,254	7,571	5,963	8,690						
<b>Non-current assets</b>		<b>1,636,468</b>	<b>1,658,331</b>	<b>1,616,963</b>	<b>1,631,993</b>	<b>Non-current liabilities</b>		<b>125,515</b>	<b>114,566</b>	<b>140,381</b>	<b>129,210</b>
Long-term assets						Provision for lawsuits	15.1	89,605	81,994	93,744	86,636
Interest earning bank deposits	4	538,771	539,081	538,771	539,081	Taxes and contributions payable	13	-	-	294	303
Valued at amortized cost		538,771	539,081	538,771	539,081	Lease liabilities	16	10,959	11,460	18,766	19,010
Deferred income tax and social contribution	7.1	8,302	25,879	15,445	32,346	Other accounts payable	14	24,951	21,112	27,577	23,261
Other non-current assets		81,706	79,972	83,987	82,264						
Judicial and tax deposits	7.2	33,019	32,104	34,313	33,435	<b>Shareholders' equity</b>		<b>1,364,464</b>	<b>1,227,769</b>	<b>1,364,773</b>	<b>1,228,233</b>
Other credits receivable		13,698	13,697	14,286	14,268	Capital	17.1	851,017	851,017	851,017	851,017
Recoverable taxes	5	34,989	34,171	35,388	34,561	Capital reserves	17.2	(35,610)	(35,610)	(35,610)	(35,610)
Investments	8	80,724	86,656	6,364	6,121	Profit reserves:	17.3	492,290	492,290	492,290	492,290
Property, plant and equipment	9	27,367	29,345	50,354	52,154	Additional dividend proposed	17.5	81,000	81,000	81,000	81,000
Intangible assets	10	899,598	897,398	922,042	920,027	Profit reserves - other		411,290	411,290	411,290	411,290
						(-) Treasury shares	17.4	(79,436)	(71,572)	(79,436)	(71,572)
						Other comprehensive income		(8,772)	(8,356)	(8,772)	(8,356)
						Retained earnings		144,975	-	144,975	-
						Non-controlling interest		-	-	309	464
<b>Total assets</b>		<b>2,183,611</b>	<b>2,067,888</b>	<b>2,235,903</b>	<b>2,122,069</b>	<b>Total liabilities and shareholders' equity</b>		<b>2,183,611</b>	<b>2,067,888</b>	<b>2,235,903</b>	<b>2,122,069</b>

## Notes to the financial statements

## Notes to the individual and consolidated, condensed interim financial statements

March 31, 2025 and 2024, and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

## Statement of income

(in thousands of reais, unless otherwise indicated)

	Note	Company		Consolidated	
		Period ended		Period ended	
		03/31/2025	03/31/2024	03/31/2025	03/31/2024
<b>Revenue from sales of goods and/or services</b>	<b>19</b>				
Insurance revenue (PAA)		443,468	409,733	447,979	422,880
Insurance revenue (BBA)		129,333	121,373	129,333	121,373
Sales of goods and services		-	-	10,488	10,248
		<b>572,801</b>	<b>531,106</b>	<b>587,800</b>	<b>554,501</b>
<b>Cost of assets and services rendered</b>					
Insurance costs	<b>20</b>	(335,028)	(347,007)	(332,100)	(345,470)
<b>Gross Income</b>		<b>237,773</b>	<b>184,099</b>	<b>255,700</b>	<b>209,031</b>
<b>Operating revenues and expenses</b>					
Sales expenses		-	-	(1,431)	(1,972)
General and administrative expenses		(13,951)	(12,410)	(30,132)	(27,252)
Equity in net income of subsidiaries	<b>8</b>	1,827	5,848	1,778	1,056
Other operating revenues (expenses)		4,548	7,177	5,728	6,385
		<b>(7,576)</b>	<b>615</b>	<b>(24,057)</b>	<b>(21,783)</b>
<b>Income (loss) before financial income (loss) and taxes</b>		<b>230,197</b>	<b>184,714</b>	<b>231,643</b>	<b>187,248</b>
<b>Financial income (loss)</b>	<b>21</b>				
Financial revenues		31,140	35,378	32,251	36,246
Financial expenses		(16,139)	(11,884)	(17,081)	(12,621)
		<b>15,001</b>	<b>23,494</b>	<b>15,170</b>	<b>23,625</b>
<b>Income (loss) before income tax</b>		<b>245,198</b>	<b>208,208</b>	<b>246,813</b>	<b>210,873</b>
<b>Income tax and social contribution</b>	<b>22</b>				
Current		(58,033)	(68,234)	(60,683)	(71,156)
Deferred		(17,441)	6,763	(16,561)	6,972
		<b>169,724</b>	<b>146,737</b>	<b>169,569</b>	<b>146,689</b>
<b>Net income for the period</b>		<b>169,724</b>	<b>146,737</b>	<b>169,569</b>	<b>146,689</b>
<b>Attributable to:</b>					
Company's shareholders		-	-	169,724	146,737
Non-controlling shareholders		-	-	(155)	(48)
<b>Earnings per share:</b>	<b>23</b>				
Basic		0.31097	0.26559	0.31097	0.26559
Diluted		0.31097	0.26559	0.31097	0.26559

See the accompanying notes to the financial statements.



## Notes to the financial statements

## Notes to the individual and consolidated, condensed interim financial statements

March 31, 2025 and 2024, and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

## Statement of income

(in thousands of reais, unless otherwise indicated)

	Company		Consolidated	
	Period ended		Period ended	
	03/31/2025	03/31/2024	03/31/2025	03/31/2024
Net income for the period	169,724	146,737	169,569	146,689
Other comprehensive income	(416)	(4,126)	(416)	(4,126)
Items that will be subsequently reclassified to the income (loss) for the period:				
Accumulated translation adjustment	(717)	571	(723)	578
Other comprehensive income of investees recognized under the equity method	41	(68)	41	(68)
Other comprehensive income, net	266	(4,636)	266	(4,636)
Equity valuation adjustments of investees recognized under the equity method	(6)	7		
Comprehensive income for the period	169,308	142,611	169,153	142,563
Attributable to:				
Company's shareholders	-	-	169,308	142,611
Non-controlling shareholders	-	-	(155)	(48)

See the accompanying notes to the financial statements.

## Notes to the financial statements

## Notes to the individual and consolidated, condensed interim financial statements

March 31, 2025 and 2024, and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

## Statement of changes in shareholders' equity

(In thousands of reais)

	Note	Capital	Capital reserves	Profit reserves	Retained earning	Treasury shares	Other comprehensive income	Shareholders' equity	Non-controlling interest	Shareholders' equity - Consolidated
<b>Balance at December 31, 2023</b>		851,017	(35,610)	561,679	-	-	9,908	1,386,994	680	1,387,674
<b>Capital transactions with partners</b>		-	-	(161,492)	(447,141)	(71,572)	-	(680,205)	(105)	(680,310)
Treasury shares acquired	17.4	-	-	-	-	(71,572)	-	(71,572)	-	(71,572)
Dividends	17.5	-	-	-	(281,905)	-	-	(281,905)	-	(281,905)
Interest on own capital	17.5	-	-	-	(84,236)	-	-	(84,236)	-	(84,236)
Additional dividend proposed	17.5	-	-	(161,492)	(81,000)	-	-	(242,492)	(105)	(242,597)
<b>Total comprehensive income</b>		-	-	5,663	533,581	-	-	539,244	(111)	539,133
Net income for the period		-	-	-	539,244	-	-	539,244	(111)	539,133
Adjustment to net income for the period (accounting practice difference)		-	-	5,663	(5,663)	-	-	-	-	-
<b>Other comprehensive income</b>		-	-	-	-	-	(18,264)	(18,264)	-	(18,264)
Translation adjustments in the period		-	-	-	-	-	751	751	-	751
Other comprehensive income		-	-	-	-	-	(18,773)	(18,773)	-	(18,773)
Other comprehensive income of investees recognized under the equity method		-	-	-	-	-	(242)	(242)	-	(242)
<b>Internal changes in shareholders' equity</b>		-	-	86,440	(86,440)	-	-	-	-	-
Formation of reserves	17.3	-	-	86,440	(86,440)	-	-	-	-	-
<b>Balance at December 31, 2024</b>		851,017	(35,610)	492,290	-	(71,572)	(8,356)	1,227,769	464	1,228,233
<b>Capital transactions with partners</b>		-	-	-	(24,749)	(7,864)	-	(32,613)	-	(32,613)
Treasury shares acquired	17.4	-	-	-	-	(7,864)	-	(7,864)	-	(7,864)
Interest on own capital	17.5	-	-	-	(24,749)	-	-	(24,749)	-	(24,749)
<b>Total comprehensive income</b>		-	-	-	169,724	-	-	169,724	(155)	169,569
Net income for the period		-	-	-	169,724	-	-	169,724	(155)	169,569
<b>Other comprehensive income</b>		-	-	-	-	-	(416)	(416)	-	(416)
Conversion adjustments		-	-	-	-	-	(723)	(723)	-	(723)
Other comprehensive income		-	-	-	-	-	266	266	-	266
Other comprehensive income of investees recognized under the equity method		-	-	-	-	-	41	41	-	41
<b>Balance at March 31, 2025</b>		851,017	(35,610)	492,290	144,975	(79,436)	(8,772)	1,364,464	309	1,364,773

See the accompanying notes to the financial statements.

## Notes to the financial statements

## Notes to the individual and consolidated, condensed interim financial statements

March 31, 2025 and 2024, and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

## Statement of Cash Flows (Indirect method)

(in thousands of reais, unless otherwise indicated)

	Company		Consolidated	
	Period ended		Period ended	
	03/31/2025	03/31/2024	03/31/2025	03/31/2024
<b>Flows from operating activities</b>				
Net income for the period	169,724	146,737	169,569	146,689
Depreciation and amortization	12,889	12,051	14,932	14,345
Net inflation adjustments	942	(2,848)	1,006	(2,816)
Provisions for lawsuits	980	460	953	488
Disposal of non-current assets and other	1,053	279	1,053	325
Equity in net income of subsidiaries	(1,827)	(5,848)	(1,778)	(1,056)
Provision for credit losses	(723)	(141)	(2,750)	(112)
Income tax and social contribution	75,474	61,471	77,244	64,184
	<b>258,512</b>	<b>212,161</b>	<b>260,229</b>	<b>222,047</b>
<b>Changes in assets and liabilities</b>				
Interest earning bank deposits measured at fair value through profit or loss	(112,236)	(166,976)	(114,479)	(167,594)
current	(10,983)	44,810	(8,806)	44,003
Inventories	-	-	50	1,422
Long-term assets (non-current)	82	2,578	207	2,526
Assets and liabilities of insurance and reinsurance contracts	(23,984)	3,841	(18,874)	(1,955)
Tax obligations (taxes payable)	(1,203)	(925)	(2,781)	(1,414)
Labor obligations, suppliers, and other accounts payable	2,223	94	3,732	3,948
Long-term liabilities (non-current liabilities)	7,208	5,743	5,671	5,181
	<b>119,619</b>	<b>101,326</b>	<b>124,949</b>	<b>108,164</b>
Interest paid	(523)	(9)	(555)	(21)
Income tax and social contribution paid	(68,071)	(52,163)	(70,925)	(54,737)
<b>Increase in cash generated from operating activities</b>	<b>51,025</b>	<b>49,154</b>	<b>53,469</b>	<b>53,406</b>
<b>Flow from investment activities</b>				
Acquisition of property, plant and equipment	(20)	(135)	(444)	(397)
Acquisition of intangible assets	(14,144)	(13,327)	(14,178)	(13,344)
Dividends received from subsidiaries and jointly-controlled subsidiaries	1,575	4,625	1,575	1,625
Interest earning bank deposits measured at amortized cost	(3,693)	(21,723)	(3,693)	(21,723)
<b>Decrease in cash used in investment activities</b>	<b>(16,282)</b>	<b>(30,560)</b>	<b>(16,740)</b>	<b>(33,839)</b>
<b>Flow from financing activities</b>				
Dividends and interest on own capital paid	(21,642)	(19,580)	(21,642)	(19,726)
Acquisition of own shares - Treasury	(7,864)	-	(7,864)	-
Payment of lease	(699)	(673)	(2,137)	(1,380)
<b>Decrease in cash used in financing activities</b>	<b>(30,205)</b>	<b>(20,253)</b>	<b>(31,643)</b>	<b>(21,106)</b>
<b>Increase (Decrease) in cash and cash equivalents</b>	<b>4,538</b>	<b>(1,659)</b>	<b>5,086</b>	<b>(1,539)</b>
<b>Cash and cash equivalents</b>				
Opening balance	15,783	13,615	16,531	14,391
Closing balance	20,321	11,956	21,617	12,852
<b>Increase (Decrease) in cash and cash equivalents</b>	<b>4,538</b>	<b>(1,659)</b>	<b>5,086</b>	<b>(1,539)</b>

See the accompanying notes to the financial statements.

## Notes to the financial statements

## Notes to the individual and consolidated, condensed interim financial statements

March 31, 2025 and 2024, and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

## Statement of added value

(In thousands of reais)

	Company		Consolidated	
	03/31/2025	03/31/2024	03/31/2025	03/31/2024
<b>Revenues</b>	<b>573,524</b>	<b>531,247</b>	<b>593,799</b>	<b>558,236</b>
Sale of goods, products and services	572,801	531,106	577,312	544,253
Sales of goods and services	-	-	13,737	13,871
Provision for credit losses	723	141	2,750	112
<b>Inputs acquired from third parties</b>	<b>(258,510)</b>	<b>(268,940)</b>	<b>(249,294)</b>	<b>(262,472)</b>
Costs of products, goods, and services sold	(215,342)	(220,768)	(211,628)	(218,015)
Materials, energy, outsourced services and other	(4,429)	(4,706)	(4,294)	(5,867)
<b>Other</b>	<b>(38,739)</b>	<b>(43,466)</b>	<b>(33,372)</b>	<b>(38,590)</b>
Other operating revenues (expenses)	2,844	(3,300)	4,587	(3,965)
Sales expenses	-	-	(1,431)	(1,972)
Administrative expenses	(41,583)	(40,166)	(36,528)	(32,653)
<b>Gross added value</b>	<b>315,014</b>	<b>262,307</b>	<b>344,505</b>	<b>295,764</b>
<b>Retentions</b>	<b>(12,889)</b>	<b>(12,051)</b>	<b>(14,932)</b>	<b>(14,345)</b>
Depreciation and amortization	(12,889)	(12,051)	(14,932)	(14,345)
<b>Net added value produced</b>	<b>302,125</b>	<b>250,256</b>	<b>329,573</b>	<b>281,419</b>
<b>Added value received as transfer</b>	<b>32,967</b>	<b>41,226</b>	<b>34,029</b>	<b>37,302</b>
Equity in net income of subsidiaries	1,827	5,848	1,778	1,056
Financial revenues	31,140	35,378	32,251	36,246
<b>Total added value payable</b>	<b>335,092</b>	<b>291,482</b>	<b>363,602</b>	<b>318,721</b>
<b>Distribution of added value</b>	<b>335,092</b>	<b>291,482</b>	<b>363,602</b>	<b>318,721</b>
<b>Personnel</b>	<b>37,379</b>	<b>38,498</b>	<b>55,800</b>	<b>56,543</b>
Direct remuneration	29,385	30,020	43,389	43,480
Benefits	6,189	6,719	9,765	10,366
Severance Pay Fund (FGTS)	1,805	1,759	2,646	2,697
<b>Taxes, rates and contributions</b>	<b>111,448</b>	<b>94,176</b>	<b>120,172</b>	<b>102,461</b>
Federal	102,302	86,184	109,760	92,987
State	1	17	100	113
Municipal	9,145	7,975	10,312	9,361
<b>Third-party capital remuneration</b>	<b>16,541</b>	<b>12,071</b>	<b>18,061</b>	<b>13,028</b>
Rentals	402	187	980	407
Other	16,139	11,884	17,081	12,621
<b>Remuneration of own capital</b>	<b>169,724</b>	<b>146,737</b>	<b>169,569</b>	<b>146,689</b>
Interest on own capital	24,749	22,779	24,749	22,779
Retained earnings for the period	144,975	123,958	144,975	123,958
Minority interest in retained earnings	-	-	(155)	(48)

See the accompanying notes to the financial statements.

## Notes to the financial statements

### Notes to the individual and consolidated, condensed interim financial statements

March 31, 2025 and 2024, and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

## 1. Operations and general information

Odontoprev S.A. (Company or Odontoprev) is a publicly-held corporation located at Alameda Araguaia, 2104, 21º andar, Alphaville – Barueri, São Paulo – Brazil.

The Company started operating on August 28, 1987 and is engaged in providing private dental care plans, the management, sale or availability of these plans to corporations and/or individuals, as well holding interests, as partner, shareholder or unitholder in other civil or commercial companies, in commercial enterprises of any nature, in Brazil and/or overseas, and the management of its own assets and/or those of third parties.

The Company is classified as a dental operator in the tertiary sector, according to Normative Resolution (RN) 531 of May 02, 2022 of the National Agency of Supplementary Health (ANS).

The Odontoprev's shares are traded on B3 under the ticker "ODPV3" and has been listed in the corporate governance segment called Novo Mercado (New Market) since December 01, 2006.

On March 31, 2025, the Company declares that it is able to take to maturity the interest earning bank deposits classified in the "amortized cost" category.

The Company holds direct and indirect interests in the following companies:

	Interest in capital (%)							
	03/31/2025				12/31/2024			
	Subsidiaries		Indirect associated company	Joint control	Subsidiaries		Indirect associated company	Joint control
	Direct	Indirect			Direct	Indirect		
<b>COMPANIES:</b>								
Odontoprev Serviços Ltda. (Odontoprev Serviços)	100.0	-	-	-	100.0	-	-	-
Easy Software S.A. (Easy Software)	-	51.0	-	-	-	51.0	-	-
Dental Partner Comércio de Produtos e Equipamentos Odontológicos Ltda. (Dental Partner)	-	100.0	-	-	-	100.0	-	-
SF 210 Participações Societárias S.A. (SF 210)	-	-	18.1	-	-	-	18.1	-
Clidec Participações S.A. (Clidec Participações) <sup>1</sup>	-	-	-	-	-	100.0	-	-
Machiron Desenvolvimento de Sistemas S.A. (MaChiron)	-	-	20.0	-	-	-	20.0	-
<b>TERTIARY SEGMENT DENTAL OPERATOR – RN 531 ANS:</b>								
Brasilidental Operadora de Planos Odontológicos S.A. (Brasilidental)	-	-	-	25.0	-	-	-	25.0
<b>NETWORK OF DENTAL AND RADIOLOGICAL CLINICS:</b>								
Clidec – Clínica Dentária Especializada Cura D'ars Ltda. (Clidec)	100.0	-	-	-	100.0	-	-	-
Boutique Dental Ltda. (Boutique Dental)	-	100.0	-	-	-	100.0	-	-
Clínicas Radiológicas Papaiz (Papaiz) <sup>1</sup>	-	100.0	-	-	-	100.0	-	-
Lúmax Radiologia e Tomografia Odontológica Ltda (Lúmax) <sup>1</sup>	-	-	-	-	-	100.0	-	-
<b>COMPANIES IN MEXICO:</b>								
Odontored CV Sociedad Anónima de Capital Variable (Odontored)	100.0	-	-	-	100.0	-	-	-
Oprev Administradora Sociedad Anónima de Capital Variable (Oprev)	-	100.0	-	-	-	100.0	-	-

<sup>1</sup>On January 2, 2025, the Extraordinary General Meeting (EGM) approved the merger of the indirect subsidiaries Clidec Participações and Lúmax, by the company Papaiz, both indirect subsidiaries of the Company.

## Approval of condensed interim financial statements

The authorization and approval to issue these individual and consolidated, condensed interim financial statements were given by the Board of Directors (BD) in a meeting held on May 6, 2025.

## Notes to the financial statements

### Notes to the individual and consolidated, condensed interim financial statements

March 31, 2025 and 2024, and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

## 2. Description of significant, material accounting policies

### 2.1. Preparation basis

The Company's individual interim condensed financial statements were prepared in accordance with technical pronouncement CPC 21 (R1) – "Interim Financial Reporting", and the interim condensed financial statements were prepared in accordance with technical pronouncement CPC 21 (R1) – "Interim Financial Reporting", equivalent to IAS 34, issued by the International Accounting Standards Board (IASB), according to the going concern assumption. Moreover, all relevant information specific to the financial statements, and only such information, is being evidenced, and corresponds to the information used by the Management in Company's administration.

The individual, consolidated and condensed interim financial statements were prepared and are being presented in accordance with the requirements of the Brazilian Securities and Exchange Commission (CVM).

According to CVM/SNC/SEP Circular Letter 003/2011, this quarterly information is presented in line with the concept of selected explanatory notes without repeating certain explanatory notes previously disclosed, but with an indication of the changes that occurred in the period and, therefore, must be read together with the annual financial statements for the year ended December 31, 2024, disclosed to the CVM on February 26, 2025. The lists of these explanatory notes are presented below:

Note	Title	Situation	Page on DFP (*)
1	Operations and general information	(a)	46
2	Description of significant accounting policies	(a)	47
3	Estimates and accounting judgements	(b)	59
4	Risk management	(b)	59
9.3	Other credits receivable	(b)	66
13	Minimum capital	(a)	69
17.2 (a)	Social security and labor	(b)	77
17.2 (b)	Civil	(b)	77
17.2 (c)	Tax assessment notices - stock options	(b)	77
17.3	Other liabilities	(b)	79
17.4	Investments payable	(b)	79
19.3	Profit reserves	(a)	80
19.5	Allocation of profits	(c)	81

(a) Note presented with reduced content when compared to the financial statements as of December 31, 2024.

(a) Note not presented since there was no change in accounting policies and no unusual transactions, when compared with the financial statements as of December 31, 2024.

(c) Note not presented since condensed interim financial statements are not applicable.

(\*) Page where the explanatory note is located in the Standardized Financial Statements (DFP) for the year ended December 31, 2024, available on the Brazilian Securities Commission (CVM) website ([www.cvm.gov.br](http://www.cvm.gov.br)) and on the Company's website (<https://ri.odontoprev.com.br>).

### 2.2. Standards and interpretations issued not in force

#### CVM Resolution 193/2023

The CVM published on October 20, 2023, effective as of November 1, 2023, Resolution CVM 193, which allows publicly-held companies to voluntarily prepare and disclose a sustainability-related financial information report based on the international standard (IFRS S1 and S2) issued by the International Sustainability Standards Board (ISSB). The adoption of this new standard will be mandatory for publicly-held companies starting from years beginning on or after

## Notes to the financial statements

## Notes to the individual and consolidated, condensed interim financial statements

March 31, 2025 and 2024, and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

January 01, 2026. The Company started the studies for implementation to meet the requirements of the new standard, according to the regulatory deadline. The Company's Management has chosen not to make this early voluntary disclosure.

## IFRS 18/2024

The International Accounting Standards Board (IASB) issued IFRS 18 - Presentation and Disclosure in Financial Statements on April 09, 2024. This standard includes requirements for all entities applying IFRS for the presentation and disclosure of information in financial statements and will replace IAS 1 - Presentation of Financial Statements, being applicable to an annual reporting period beginning on or after January 1, 2027. The Company is assessing the possible impacts of this standard.

## Complementary Law No. 214 of January 16, 2025

On January 16, 2025, the Tax on Goods and Services (IBS) was introduced at the state/municipal level, as well as the Social Contribution on Goods and Services (CBS) and the Selective Tax (IS) at the federal level, unifying five taxes — ICMS, ISS, IPI, PIS and COFINS — into a single levy as of 2033. The Company is assessing the impacts of this standard and necessary actions.

## 3. Cash and cash equivalents

	Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
Cash	6	6	77	58
Cash in transit <sup>1</sup>	15,966	9,019	15,966	9,019
Banks checking account	393	213	1,162	773
Interest earning bank deposits (remunerated current account)	3,956	6,545	4,412	6,681
	<b>20,321</b>	<b>15,783</b>	<b>21,617</b>	<b>16,531</b>

<sup>1</sup>Receipts from clients to be transferred by financial institutions, as well as monetary amounts under confirmation.

## 4. Interest earning bank deposits (financial assets at fair value through profit or loss and amortized cost)

Investment portfolio per original maturities - Company						
Average interest rate	Without maturity	01-180 days	>360 days	Book value	Fair value adjustment	Restated amount
<b>Balance at 12/31/2024</b>	<b>192,982</b>	<b>134,655</b>	<b>539,081</b>	<b>866,718</b>	<b>(54,155)</b>	<b>812,563</b>
<b>Quotas of investment funds</b>						
Fixed income inv. fund	12.50% p.a.	305,218	-	305,218	-	305,218
<b>Fair value through profit or loss</b>		<b>305,218</b>	<b>-</b>	<b>305,218</b>	<b>-</b>	<b>305,218</b>
<b>Fixed income securities - Public</b>						
National Treasury Notes – NTN						
Series B - IPCA with half-yearly interest	9.79% p.a.	-	138,658	388,805	(34,859)	492,604
Series F - Fixed rate with half-yearly interest	10.13% p.a.	-	-	149,966	(17,640)	132,326
<b>Amortized cost</b>		<b>-</b>	<b>138,658</b>	<b>538,771</b>	<b>(52,499)</b>	<b>624,930</b>
<b>Balance at 03/31/2025</b>		<b>305,218</b>	<b>138,658</b>	<b>538,771</b>	<b>(52,499)</b>	<b>930,148</b>
Current assets		305,218	138,658	-	443,876	
Non-current assets		-	-	538,771	538,771	
		<b>305,218</b>	<b>138,658</b>	<b>538,771</b>	<b>982,647</b>	

## Notes to the financial statements

## Notes to the individual and consolidated, condensed interim financial statements

March 31, 2025 and 2024, and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

		Investment portfolio per original maturities - Consolidated					
	Average interest rate	Without maturity	01-180 days	>360 days	Book value	Fair value adjustment	Restated amount
Balance at 12/31/2024		213,489	144,302	539,081	896,872	(54,155)	842,717
Quotas of investment funds							
Fixed income inv. fund	12.50% p.a.	328,383	-	-	328,383	-	328,383
CETES	8.07% p.a.	-	9,232	-	9,232	-	9,232
Fair value through profit or loss		328,383	9,232	-	337,615	-	337,615
Fixed income securities - Public							
National Treasury Notes – NTN							
Series B - IPCA with half-yearly interest	9.79% p.a.	-	138,658	388,805	527,463	(34,859)	492,604
Series F - Fixed rate with half-yearly interest	10.13% p.a.	-	-	149,966	149,966	(17,640)	132,326
Amortized cost		-	138,658	538,771	677,429	(52,499)	624,930
Balance at 03/31/2025		328,383	147,890	538,771	1,015,044	(52,499)	962,545
Current assets		328,383	147,890	-	476,273		
Non-current assets		-	-	538,771	538,771		
		328,383	147,890	538,771	1,015,044		

**Investment funds (fixed income inv. fund):** investment fund quotas on Bradesco FI RF Bond and BRAM FI RF Referenced DI Coral which are measured based on the quota values disclosed by the administrator institution Bradesco Asset Management.

**Certificados de la Tesorería de la Federación (CETES):** fixed-income government bonds held by Odontored issued by the Mexican government. The fair value of the investment was obtained as disclosed by the Bank of Mexico.

**National Treasury Notes - Series B (NTN-B) - Treasury IPCA with twice-yearly interest:** federal government bonds, refer to the assets from managed portfolios, which are managed by Bradesco Asset Management. Government bonds had their fair values obtained from average rate tables, published by the ANBIMA (Brazilian Association of Financial and Capital Market Entities).

**National Treasury Notes - Series F (NTN-F) - Fixed rate Treasury with twice-yearly interest:** federal government bonds, refer to the assets from managed portfolios, which are managed by Bradesco Asset Management. Government bonds had their fair values obtained from average rate tables, published by the ANBIMA (Brazilian Association of Financial and Capital Market Entities).

		Changes in investment portfolio - Company				
	Fair value through profit or loss	Amortized cost				
	Fixed income inv. fund	NTN-B	NTN-F	LTN	Total	Total balance
<b>Balance at 12/31/2023</b>	<b>180,916</b>	<b>604,660</b>	<b>153,350</b>	<b>10,845</b>	<b>768,855</b>	<b>949,771</b>
Investments	1,335,748	34,994	-	-	34,994	1,370,742
(-) Redemptions <sup>1</sup>	(1,364,114)	(174,635)	(14,238)	(11,499)	(200,372)	(1,564,486)
Earnings	40,432	55,097	14,508	654	70,259	110,691
<b>Balance at 12/31/2024</b>	<b>192,982</b>	<b>520,116</b>	<b>153,620</b>	<b>-</b>	<b>673,736</b>	<b>866,718</b>
Investments	331,984	-	-	-	-	331,984
(-) Redemptions <sup>1</sup>	(227,667)	(8,681)	(7,120)	-	(15,801)	(243,468)
Earnings	7,919	16,028	3,466	-	19,494	27,413
<b>Balance at 03/31/2025</b>	<b>305,218</b>	<b>527,463</b>	<b>149,966</b>	<b>-</b>	<b>677,429</b>	<b>982,647</b>

<sup>1</sup> Redemptions of securities at amortized cost refer to the maturity of the respective securities.



## Notes to the financial statements

## Notes to the individual and consolidated, condensed interim financial statements

March 31, 2025 and 2024, and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

	Changes in investment portfolio - Consolidated							
	Fair value through profit or loss			Amortized cost			Total balance	
	Fixed income inv. fund	CETES	Total	NTN-B	NTN-P	LTN		Total
Balance at 12/31/2023	199,104	9,799	208,903	604,660	153,350	10,845	768,855	977,758
Investments	1,437,148	108,877	1,546,025	34,994	-	-	34,994	1,581,019
(-) Redemptions¹	(1,465,626)	(110,035)	(1,575,661)	(174,635)	(14,238)	(11,499)	(200,372)	(1,776,033)
Earnings	42,863	1,006	43,869	55,097	14,508	654	70,259	114,128
Balance at 12/31/2024	213,489	9,647	223,136	520,116	153,620	-	673,736	896,872
Investments	358,414	229,396	587,810	-	-	-	-	587,810
(-) Redemptions¹	(252,160)	(230,035)	(482,195)	(8,681)	(7,120)	-	(15,801)	(497,996)
Earnings	8,640	224	8,864	16,028	3,466	-	19,494	28,358
Balance at 03/31/2025	328,383	9,232	337,615	527,463	149,966	-	677,429	1,015,044

<sup>1</sup> Redemptions of securities at amortized cost refer to the maturity of the respective securities.

## 5. Tax and social security credits

	Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
IRPJ	39,567	27,273	43,375	30,897
CSLL	11,352	6,897	13,414	9,176
INSS	5,903	5,646	5,903	5,646
ISS	1,419	1,455	1,436	1,472
PIS and COFINS	139	137	413	1,218
IRRF	127	127	1,061	977
Other	-	-	682	1,028
	<b>58,507</b>	<b>41,535</b>	<b>66,284</b>	<b>50,414</b>
Current assets	23,518	7,364	30,896	15,853
Non-current assets	34,989	34,171	35,388	34,561
	<b>58,507</b>	<b>41,535</b>	<b>66,284</b>	<b>50,414</b>

**Corporate income tax (IRPJ) and social contribution (CSLL):** corporate income tax (IRPJ) balance composed of advances from the current and previous years, and social contribution (CSLL) balance composed of credits from previous years, both arising from technological innovation, subject to approval by the MCTI (Ministry of Science, Technology and Innovation).

## 6. Other accounts receivable

	Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
Advances to suppliers and other advances	232	2,402	3,835	6,364
Advances to employees	9,007	9,054	10,377	10,504
Dividends receivable <sup>1</sup>	5,500	-	-	-
Other credits receivable <sup>2</sup>	13,612	14,245	33,527	34,881
	<b>28,351</b>	<b>25,701</b>	<b>47,739</b>	<b>51,749</b>

<sup>1</sup> Dividends receivable from direct subsidiaries, see Note 8.<sup>2</sup> Refers mainly to customers for sales and goods and services and revenue from post-payment contracts.

## Notes to the financial statements

## Notes to the individual and consolidated, condensed interim financial statements

March 31, 2025 and 2024, and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

## 7. Long-term assets

## 7.1. Income tax e Social contribution Deferred assets

Timing differences	Realization estimate	Company				Consolidated			
		12/31/2024	Formation	Realization	03/31/2025	12/31/2024	Formation	Realization	03/31/2025
Provision for lawsuits (Contingencies)	>12 months	13,267	2,242	-	15,509	13,854	2,220	-	16,074
Sundry provisions	≤12 months	3,717	-	(1,424)	2,293	3,765	-	(1,435)	2,330
ILP Program	≤12 months and >12 months	9,341	977	-	10,318	10,425	1,137	-	11,562
Profit sharing	≤12 months	6,238	1,422	-	7,660	7,385	1,727	-	9,112
CPC 50/IFRS 17 effect	>12 months	30,280	-	(2,563)	27,717	29,973	-	(1,823)	28,150
Other	≤12 months	19,955	-	(4,745)	15,210	23,863	-	(5,241)	18,622
<b>Deferred IRPJ/CSLL (Assets)</b>		<b>82,798</b>	<b>4,641</b>	<b>(8,732)</b>	<b>78,707</b>	<b>89,265</b>	<b>5,084</b>	<b>(8,499)</b>	<b>85,850</b>
Amortization of goodwill	>12 months	(56,919)	(457)	-	(57,376)	(56,919)	(457)	-	(57,376)
Insurance contract liabilities	≤12 months	-	(13,029)	-	(13,029)	-	(13,029)	-	(13,029)
<b>Deferred IRPJ/CSLL (Liabilities)</b>		<b>(56,919)</b>	<b>(13,486)</b>	<b>-</b>	<b>(70,405)</b>	<b>(56,919)</b>	<b>(13,486)</b>	<b>-</b>	<b>(70,405)</b>
<b>Deferred IRPJ/CSLL</b>		<b>25,879</b>	<b>(8,845)</b>	<b>(8,732)</b>	<b>8,302</b>	<b>32,346</b>	<b>(8,402)</b>	<b>(8,499)</b>	<b>15,445</b>
Deferred income tax (IRPJ)		19,030	(6,514)	(6,410)	6,106	23,701	(6,178)	(6,054)	11,469
Deferred social contribution (CSLL)		6,849	(2,331)	(2,322)	2,196	8,645	(2,224)	(2,445)	3,976
<b>Deferred IRPJ/CSLL</b>		<b>25,879</b>	<b>(8,845)</b>	<b>(8,732)</b>	<b>8,302</b>	<b>32,346</b>	<b>(8,402)</b>	<b>(8,499)</b>	<b>15,445</b>

## 7.2. Judicial and tax deposits

	Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
<b>Tax</b>	<b>30,690</b>	<b>29,857</b>	<b>31,884</b>	<b>31,051</b>
ISS <sup>1</sup>	29,013	28,211	29,013	28,211
Other	1,677	1,646	2,871	2,840
<b>Social security and labor</b>	<b>401</b>	<b>395</b>	<b>501</b>	<b>532</b>
<b>Civil</b>	<b>1,928</b>	<b>1,852</b>	<b>1,928</b>	<b>1,852</b>
	<b>33,019</b>	<b>32,104</b>	<b>34,313</b>	<b>33,435</b>

<sup>1</sup>From the merged company Odonto System, the full amount of the Service Tax – ISS was deposited in court without deducting the events from the calculation basis (object of the lawsuit). Amount fully provisioned in non-current liabilities under “Provisions for lawsuits.”

## 8. Investments

Changes in investments:	Company				
	Balance at 12/31/2024	Dividends	Equity in net income of subsidiaries	Other comprehensive income	Balance at 03/31/2025
<b>Direct subsidiaries</b>					
Odontored	14,563	-	(2,458)	(717)	11,388
Clidec	46,517	(2,000)	1,396	-	45,913
Odontoprev Serviços	21,229	(3,500)	1,127	(7)	18,849
<b>Jointly-controlled subsidiary</b>					
Brasildental	4,346	(1,575)	1,762	40	4,573
<b>Other investments</b>					
Other	1	-	-	-	1
<b>Total</b>	<b>86,656</b>	<b>(7,075)</b>	<b>1,827</b>	<b>(684)</b>	<b>80,724</b>

## Notes to the financial statements

Notes to the individual and consolidated, condensed interim financial statements

March 31, 2025 and 2024, and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

Consolidated					
Changes in investments:	Balance at 12/31/2024	Dividends	Equity in net income of subsidiaries	Other comprehensive income	Balance at 03/31/2025
<b>Jointly-controlled subsidiary</b>					
Brasil dental	4,346	(1,575)	1,762	40	4,573
<b>Associated companies</b>					
MaChiron	41	-	(19)	-	22
SF 210	1,678	-	35	-	1,713
<b>Other investments</b>					
Other	56	-	-	-	56
<b>Total</b>	<b>6,121</b>	<b>(1,575)</b>	<b>1,778</b>	<b>40</b>	<b>6,364</b>

Company and Consolidated						
Position as of 03/31/2025	Subsidiaries:			Affiliates:		Joint Venture:
	Odontoprev Serviços	Clidec	Odontored	Machiron	SF210	Brasildental
Capital	9,700	31,516	6,030	595	8,859	9,500
Interest (%)	100.0	100.0	100.0	20.0	18.1	25.0
Assets	38,407	54,760	17,639	165	9,467	31,573
Liabilities	19,558	8,847	6,251	95	24	13,280
Shareholders' equity	18,849	45,913	11,388	70	9,443	18,293
Revenues	13,038	9,726	4,538	262	-	27,245
Income (loss) for the year	1,127	1,396	(2,458)	(93)	195	7,046
Dividends	(3,500)	(2,000)	-	-	-	(1,575)
Equity in net income of subsidiaries	1,127	1,396	(2,458)	(19)	35	1,762

## 9. Property, plant and equipment

	Changes in property, plant and equipment - Company								
	12/31/2024	Acquisitions	Write-offs	Depreciation / Amortization	03/31/2025	Cost	Accumulated depreciation	Book balance, net	Depreciation rate (% p.a.)
IT equipment	10,917	10	-	(958)	9,969	21,737	(11,768)	9,969	20
Vehicles	1,247	-	(3)	(88)	1,156	1,859	(703)	1,156	20
Facilities	605	-	-	(18)	587	746	(159)	587	10
Machinery and equipment	504	-	-	(18)	486	832	(346)	486	10
Furniture and fixtures	643	10	-	(35)	618	1,797	(1,179)	618	10
Communication equipment	16	-	-	(1)	15	48	(33)	15	10
Dental equipment	64	-	-	(3)	61	168	(107)	61	10
<b>Total for own use</b>	<b>13,996</b>	<b>20</b>	<b>(3)</b>	<b>(1,121)</b>	<b>12,892</b>	<b>27,187</b>	<b>(14,295)</b>	<b>12,892</b>	
Other property, plant, and equipment (improvements)	4,317	-	-	(397)	3,920	10,134	(6,214)	3,920	20
<b>Total other property, plant and equipment</b>	<b>18,313</b>	<b>20</b>	<b>(3)</b>	<b>(1,518)</b>	<b>16,812</b>	<b>37,321</b>	<b>(20,509)</b>	<b>16,812</b>	
Right-of-use (CPC 06 (R2))/IFRS 16) <sup>1</sup>	11,032	3	-	(480)	10,555	17,455	(6,900)	10,555	
<b>Total property, plant and equipment</b>	<b>29,345</b>	<b>23</b>	<b>(3)</b>	<b>(1,998)</b>	<b>27,367</b>	<b>54,776</b>	<b>(27,409)</b>	<b>27,367</b>	

<sup>1</sup> Depreciation calculated according to the duration of the real estate and machinery and equipment lease contract.

## Notes to the financial statements

## Notes to the individual and consolidated, condensed interim financial statements

March 31, 2025 and 2024, and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

	Changes in property, plant and equipment - Consolidated								
	12/31/2024	Acquisitions	Write-offs	Depreciation / Amortization	03/31/2025	Cost	Accumulated depreciation	Book balance, net	
IT equipment	11,570	201	-	(1,071)	10,700	24,713	(14,013)	10,700	20
Vehicles	1,444	-	(3)	(103)	1,338	2,141	(803)	1,338	20
Facilities	776	-	-	(24)	752	960	(208)	752	10
Machinery and equipment	6,050	66	-	(286)	5,830	12,977	(7,147)	5,830	10
Furniture and fixtures	1,466	52	-	(69)	1,449	3,486	(2,037)	1,449	10
Communication equipment	24	2	-	(1)	25	81	(56)	25	10
Dental equipment	2,031	10	-	(78)	1,963	3,718	(1,755)	1,963	10
<b>Total for own use</b>	<b>23,361</b>	<b>331</b>	<b>(3)</b>	<b>(1,632)</b>	<b>22,057</b>	<b>48,076</b>	<b>(26,019)</b>	<b>22,057</b>	
Other property, plant, and equipment (improvements)	7,077	113	(16)	(656)	6,518	19,729	(13,211)	6,518	20
<b>Total other property, plant and equipment</b>	<b>30,438</b>	<b>444</b>	<b>(19)</b>	<b>(2,288)</b>	<b>28,575</b>	<b>67,805</b>	<b>(39,230)</b>	<b>28,575</b>	
Right-of-use (CPC 06 (R2))/IFRS 16) <sup>1</sup>	21,716	1,611	-	(1,548)	21,779	38,415	(16,636)	21,779	-
<b>Total property, plant and equipment</b>	<b>52,154</b>	<b>2,055</b>	<b>(19)</b>	<b>(3,836)</b>	<b>50,354</b>	<b>106,220</b>	<b>(55,866)</b>	<b>50,354</b>	

<sup>1</sup> Depreciation calculated according to the duration of the real estate and machinery and equipment lease contract.

## 10. Intangible assets

	Company							
Cash generating unit (CGU)	12/31/2024	Additions	Write-offs	Amortizations	03/31/2025	Cost	Accumulated amortization <sup>4</sup>	Book balance, net
Odontoprev <sup>1</sup>	99,515	-	-	-	99,515	114,390	(14,875)	99,515
Bradesco Dental <sup>2</sup>	409,640	-	-	-	409,640	409,640	-	409,640
Odonto System <sup>3</sup>	145,793	-	-	-	145,793	145,793	-	145,793
Goodwill in investment acquisitions	654,948	-	-	-	654,948	669,823	(14,875)	654,948
Development of systems and software use licenses	220,934	14,144	(1,054)	(10,738)	223,286	405,179	(181,893)	223,286
Client portfolio	3,465	-	-	(134)	3,331	45,391	(42,060)	3,331
Trademarks and patents	17,943	-	-	-	17,943	22,260	(4,317)	17,943
Non-competition agreement	108	-	-	(18)	90	1,864	(1,774)	90
Allocated intangible assets	21,516	-	-	(152)	21,364	69,515	(48,151)	21,364
Intangible assets	897,398	14,144	(1,054)	(10,890)	899,598	1,144,517	(244,919)	899,598

	Consolidated							
Cash generating unit (CGU)	12/31/2024	Additions	Write-offs	Amortizations	03/31/2025	Cost	Accumulated amortization <sup>4</sup>	Book balance, net
Odontoprev <sup>1</sup>	99,515	-	-	-	99,515	114,390	(14,875)	99,515
Bradesco Dental <sup>2</sup>	409,640	-	-	-	409,640	409,640	-	409,640
Odonto System <sup>3</sup>	145,793	-	-	-	145,793	145,793	-	145,793
Various units, with non-significant goodwill <sup>5</sup>	14,521	-	-	-	14,521	14,785	(264)	14,521
Goodwill in investment acquisitions	669,469	-	-	-	669,469	684,608	(15,139)	669,469
Development of systems and software use licenses	223,532	14,178	(1,054)	(10,857)	225,799	412,956	(187,157)	225,799
Client portfolio	3,619	-	-	(140)	3,479	45,623	(42,144)	3,479
Trademarks and patents	22,154	-	-	-	22,154	26,472	(4,318)	22,154
Non-competition agreement	1,253	-	-	(112)	1,141	3,747	(2,606)	1,141
Allocated intangible assets	27,026	-	-	(252)	26,774	75,842	(49,068)	26,774
Intangible assets	920,027	14,178	(1,054)	(11,109)	922,042	1,173,406	(251,364)	922,042

<sup>1</sup>It refers to a grouping of cash-generating units from businesses acquired over time with the aim of regional expansion, products and strengthening the brand.<sup>2</sup> Integration of the activities carried out, complementing skills and creating a differentiated operation in the market.<sup>3</sup>Objective of regional expansion and products.<sup>4</sup>The accumulated amortization amounts presented refer to the tax amortization of goodwill made up to December 2013, as allowed by the Transition Tax Regime (RTT), pursuant to the legislation in force at the time. As of January 01, 2014, with the revocation of the RTT by Law 12973/2014, there was no new recognition of tax amortization of goodwill.<sup>5</sup>Acquisitions of businesses with the aim of verticalizing the operation.

The annual amortization rate for systems development and software licenses is 20%.

## 10.1. Goodwill on the acquisition of investments

The Company evaluates its recoverability through impairment tests and for goodwill from acquisitions of investments allocated to cash generating units (CGUs).

## Notes to the financial statements

### Notes to the individual and consolidated, condensed interim financial statements

March 31, 2025 and 2024, and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

As of March 31, 2025, through internal assessments, Management concluded that there was no evidence of impairment.

The last impairment test was performed on November 30, 2024 and is carried out annually by the Company.

#### 11. Minimum capital

The Company is a dental operator regulated by the Brazilian Supplementary Health Agency (ANS), which imposes regulatory limits on it with the mandatory adoption of the risk-based capital model. For this reason, the amounts and nomenclatures presented in this note follow the ANS accounting standards, i.e. disregarding the effects of CPC 50/IFRS 17, which has not been approved by this regulator.

ANS establishes the rules for recognizing technical reserves and criteria for maintaining minimum shareholders' equity in accordance with NR 569/2022.

Company: calculation of PMA, PLA, MS and CBR		
Description:	03/31/2025	12/31/2024
Reference capital	11,702	11,702
(x) K factor <sup>1</sup>	3.23%	3.23%
<b>Adjusted minimum shareholders' equity (PMA)</b>	<b>378</b>	<b>378</b>
Book value of shareholders' equity	1,418,929	1,285,651
Ownership interest in regulated entities	(4,225)	(4,166)
Deferred acquisition costs	(38,321)	(22,604)
Prepaid expenses	(5,254)	(7,571)
Intangible assets	(899,598)	(897,398)
Goodwill from indirect interests	(14,532)	(14,532)
<b>Adjusted shareholders' equity (ASE)</b>	<b>456,999</b>	<b>339,380</b>
<b>Risk-based capital (CBR)<sup>2</sup></b>	<b>306,392</b>	<b>296,780</b>
<b>Required sufficiency (PLA ANS - CBR)</b>	<b>150,607</b>	<b>42,600</b>

<sup>1</sup>K Factor corresponds to the classification: group dentistry, tertiary segment and region 1 according to appendix RN 569/2022.

<sup>2</sup>The CBR value considers the use of the reduced factors, under the terms of what was defined in article 6 of Regulatory Resolution 569/2022.

#### 12. Liabilities from insurance and reinsurance contracts

##### (a) Liabilities from insurance and reinsurance contracts

	Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
Assets for Remaining Coverage (PAA)	(25,823)	(25,501)	(29,836)	(33,316)
Liabilities for Remaining Coverage (BBA)	113,327	125,755	113,327	125,755
Liabilities claims incurred	159,172	171,532	160,837	173,643
	<b>246,676</b>	<b>271,786</b>	<b>244,328</b>	<b>266,082</b>
Assets of insurance and reinsurance contracts	(25,823)	(25,501)	(29,836)	(33,316)
Liabilities from insurance and reinsurance contracts	272,499	297,287	274,164	299,398
	<b>246,676</b>	<b>271,786</b>	<b>244,328</b>	<b>266,082</b>

## Notes to the financial statements

## Notes to the individual and consolidated, condensed interim financial statements

March 31, 2025 and 2024, and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

## (b) Remaining coverage for general model (BBA)

	Company and Consolidated	
	Period ended	
	03/31/2025	12/31/2024
Cash flows from acquisition	3,297,525	3,228,525
Events and other directly attributable expenses	6,787,740	6,673,517
<b>Estimates of present value of future cash outflow</b>	<b>10,084,939</b>	<b>9,902,042</b>
Estimates of present value of future cash inflow	(10,726,991)	(10,412,965)
Risk adjustment for non-financial risk adjustment	13,126	12,653
Contractual service margin (CSM)	742,253	624,025
<b>Net amount included in the provision of insurance contracts</b>	<b>113,327</b>	<b>125,755</b>

## (c) Realization of insurance coverage margin

	Company and Consolidated					
	≤01 year	01-02 years	02-03 years	03-04 years	04-05 years	>05 years
Direct Insurance	186,354	144,249	107,276	83,557	65,835	154,982
<b>Insurance contracts issued</b>	<b>186,354</b>	<b>144,249</b>	<b>107,276</b>	<b>83,557</b>	<b>65,835</b>	<b>154,982</b>

	Company and Consolidated					
	≤01 year	01-02 years	02-03 years	03-04 years	04-05 years	>05 years
Direct Insurance	160,172	118,698	89,823	70,422	55,488	129,422
<b>Insurance contracts issued</b>	<b>160,172</b>	<b>118,698</b>	<b>89,823</b>	<b>70,422</b>	<b>55,488</b>	<b>129,422</b>

## (d) Changes in reserves - remaining coverage

	Company				
	Liabilities for Remaining Coverage (BBA)				TOTAL
	Best outflow estimate (BEL)	Risk adjustment (RA)	Insurance coverage margin (CSM)	Subtotal	
<b>Balance at 12/31/2023</b>	<b>(668,220)</b>	<b>15,097</b>	<b>764,942</b>	<b>111,819</b>	<b>(31,125)</b>
<b>Technical changes related to the current period (insurance revenue)</b>	<b>(225,764)</b>	<b>(6,646)</b>	<b>(272,317)</b>	<b>(504,727)</b>	<b>(1,695,907)</b>
Contracts by the fair value method	(106,094)	(1,554)	(118,441)	(226,089)	(226,089)
Issue of contracts after transition (Other contracts)	(119,670)	(5,092)	(153,876)	(278,638)	(278,638)
Settlement relating to contracts premium allocation approach	-	-	-	-	(1,695,907)
<b>Technical changes related to future periods</b>	<b>(67,614)</b>	<b>2,921</b>	<b>57,872</b>	<b>(6,821)</b>	<b>(6,821)</b>
Changes in the CMS adjusting estimates	783,156	(26,189)	(792,479)	(35,512)	(35,512)
Changes in the estimates that do not adjust CSM (OCI)	29,882	(1,191)	-	28,691	(28,691)
Contracts initially recognized in the period	(880,652)	30,301	850,351	-	-
<b>Insurance expenses</b>	<b>95,618</b>	<b>-</b>	<b>-</b>	<b>95,618</b>	<b>167,330</b>
Costs of purchase	95,618	-	-	95,618	167,330
<b>Total financial expenses</b>	<b>(40,366)</b>	<b>1,281</b>	<b>73,528</b>	<b>34,443</b>	<b>-</b>
Insurance contract financial expenses	(40,366)	1,281	73,528	34,443	-
<b>Cash flows</b>	<b>395,423</b>	<b>-</b>	<b>-</b>	<b>395,423</b>	<b>1,534,201</b>
Premiums received	491,622	-	-	491,622	1,534,201
Cash flows from acquisition of insurance	(96,199)	-	-	(96,199)	-
<b>Balance at 12/31/2024</b>	<b>(510,923)</b>	<b>12,653</b>	<b>624,025</b>	<b>125,755</b>	<b>(25,501)</b>
<b>Balance at 03/31/2025</b>	<b>(642,053)</b>	<b>13,127</b>	<b>742,253</b>	<b>113,327</b>	<b>(25,823)</b>

## Notes to the financial statements

## Notes to the individual and consolidated, condensed interim financial statements

March 31, 2025 and 2024, and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

	Consolidated					
	Liabilities for Remaining Coverage (BBA)				Premium Allocation Approach (PAA)	TOTAL
	Best outflow estimate (BEL)	Risk adjustment (RA)	Insurance coverage margin (CSM)	Subtotal		
Balance at 12/31/2023	(668,220)	15,097	764,942	111,819	(32,912)	78,907
Technical changes related to the current period (insurance revenue)	(225,764)	(6,646)	(272,317)	(504,727)	(1,738,279)	(2,243,006)
Contracts by the fair value method	(106,094)	(1,554)	(118,441)	(226,089)	-	(226,089)
Issue of contracts after transition (Other contracts)	(119,670)	(5,092)	(153,876)	(278,638)	-	(278,638)
Settlement relating to contracts premium allocation approach	-	-	-	-	(1,738,279)	(1,738,279)
Technical changes related to future periods	(67,614)	2,921	57,872	(6,821)	-	(6,821)
Changes in the CMS adjusting estimates	783,156	(26,189)	(792,479)	(35,512)	-	(35,512)
Changes in the estimates that do not adjust CSM (OCI)	29,882	(1,191)	-	28,691	-	28,691
Contracts initially recognized in the period	(880,652)	30,301	850,351	-	-	-
Insurance expenses	95,618	-	-	95,618	172,681	268,299
Costs of purchase	95,618	-	-	95,618	172,681	268,299
Total financial expenses	(40,366)	1,281	73,528	34,443	-	34,443
Insurance contract financial expenses	(40,366)	1,281	73,528	34,443	-	34,443
Cash flows	395,423	-	-	395,423	1,565,194	1,960,617
Premiums received	491,622	-	-	491,622	1,565,194	2,056,816
Cash flows from acquisition of insurance	(96,199)	-	-	(96,199)	-	(96,199)
Balance at 12/31/2024	(510,923)	12,653	624,025	125,755	(33,316)	92,439
Technical changes related to the current period (insurance revenue)	(57,311)	(1,695)	(70,327)	(129,333)	(447,979)	(577,312)
Contracts by the fair value method	(24,566)	(355)	(27,162)	(52,083)	-	(52,083)
Issue of contracts after transition (Other contracts)	(32,745)	(1,340)	(43,165)	(77,250)	-	(77,250)
Settlement relating to contracts premium allocation approach	-	-	-	-	(447,979)	(447,979)
Technical changes related to future periods	(196,768)	1,795	167,199	(27,774)	-	(27,774)
Changes in the CMS adjusting estimates	42,553	(5,897)	(64,002)	(27,346)	-	(27,346)
Changes in the estimates that do not adjust CSM (OCI)	(674)	246	-	(428)	-	(428)
Contracts initially recognized in the period	(238,647)	7,446	231,201	-	-	-
Insurance expenses	25,879	-	-	25,879	30,434	56,313
Costs of purchase	25,879	-	-	25,879	30,434	56,313
Total financial expenses	(11,439)	374	21,356	10,291	-	10,291
Insurance contract financial expenses	(11,439)	374	21,356	10,291	-	10,291
Cash flows	108,509	-	-	108,509	421,025	529,534
Premiums received	128,834	-	-	128,834	421,025	549,859
Cash flows from acquisition of insurance	(20,325)	-	-	(20,325)	-	(20,325)
Balance at 03/31/2025	(642,053)	13,127	742,253	113,327	(29,836)	83,491

## (e) Changes in reserves – events incurred

	Company					
	Liabilities claims incurred - BBA			Liabilities - claims incurred - PAA		
	Best outflow estimate (BEL)	Risk adjustment (RA)	Subtotal	Best outflow estimate (BEL)	Risk adjustment (RA)	Subtotal
<b>Balance at 12/31/2023</b>	19,195	1,389	20,584	135,239	8,282	143,521
<b>Expenses from rendering of services</b>	75,482	(76)	75,406	686,799	2,636	689,435
Claims incurred and other expenses in rendering of services	228,775	10,597	239,372	1,494,424	70,961	1,565,385
Adjustments to incurred claims liabilities	(153,293)	(10,673)	(163,966)	(807,625)	(68,325)	(875,950)
<b>Insurance contract financial expenses</b>	1,843	169	2,012	-	-	-
Changes recognized in other comprehensive income	(4)	(1)	(5)	-	-	-
<b>Cash flows</b>	(81,327)	-	(81,327)	(678,094)	-	(678,094)
Claims and other expenses with rendering of insurance paid	(81,327)	-	(81,327)	(678,094)	-	(678,094)
<b>Balance at 12/31/2024</b>	15,189	1,481	16,670	143,944	10,918	154,862
<b>Expenses from rendering of services</b>	16,192	(38)	16,154	151,551	557	152,108
Claims incurred and other expenses in rendering of services	47,401	2,328	49,729	350,357	18,079	368,436
Adjustments to incurred claims liabilities	(31,209)	(2,366)	(33,575)	(198,806)	(17,522)	(216,328)
<b>Insurance contract financial expenses</b>	420	42	462	-	-	-
Changes recognized in other comprehensive income	(15)	(2)	(17)	-	-	-
<b>Cash flows</b>	(17,735)	-	(17,735)	(163,332)	-	(163,332)
Claims and other expenses with rendering of insurance paid	(17,735)	-	(17,735)	(163,332)	-	(163,332)
<b>Balance at 03/31/2025</b>	14,051	1,483	15,534	132,163	11,475	143,638

## Notes to the financial statements

## Notes to the individual and consolidated, condensed interim financial statements

March 31, 2025 and 2024, and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

	Consolidated					
	Liabilities claims incurred - BBA			Liabilities claims incurred - PAA		
	Best outflow estimate (BEL)	Risk adjustment (RA)	Subtotal	Best outflow estimate (BEL)	Risk adjustment (RA)	Subtotal
Balance at 12/31/2023	19,195	1,389	20,584	136,867	8,291	145,158
Expenses from rendering of services	75,482	(76)	75,406	679,204	2,636	681,840
Claims incurred and other expenses in rendering of services	228,775	10,597	239,372	1,486,829	70,961	1,557,790
Adjustments to incurred claims liabilities	(153,293)	(10,673)	(163,966)	(807,625)	(68,325)	(875,950)
Insurance contract financial expenses	1,843	169	2,012	-	-	-
Changes recognized in other comprehensive income	(4)	(1)	(5)	-	-	-
Cash flows	(81,327)	-	(81,327)	(670,025)	-	(670,025)
Claims and other expenses with rendering of insurance paid	(81,327)	-	(81,327)	(670,025)	-	(670,025)
Balance at 12/31/2024	15,189	1,481	16,670	146,046	10,927	156,973
Expenses from rendering of services	16,192	(38)	16,154	148,809	557	149,366
Claims incurred and other expenses in rendering of services	47,401	2,328	49,729	347,615	18,079	365,694
Adjustments to incurred claims liabilities	(31,209)	(2,366)	(33,575)	(198,806)	(17,522)	(216,328)
Insurance contract financial expenses	420	42	462	-	-	-
Changes recognized in other comprehensive income	(15)	(2)	(17)	-	-	-
Cash flows	(17,735)	-	(17,735)	(161,036)	-	(161,036)
Claims and other expenses with rendering of insurance paid	(17,735)	-	(17,735)	(161,036)	-	(161,036)
Balance at 03/31/2025	14,051	1,483	15,534	133,819	11,484	145,303

## (f) Insurance coverage margin

	Company and Consolidated		
	Contracts assessed through the fair value in the transition	Issue of contracts after transition (Other contracts)	Total
Balance at 12/31/2023	460,446	304,496	764,942
CSM recognized for services rendered	(118,441)	(153,876)	(272,317)
Changes regarding the current service	(118,441)	(153,876)	(272,317)
Contracts initially recognized in the period	-	850,351	850,351
Changes in the CMS adjusting estimates	(29,295)	(763,184)	(792,479)
Changes regarding the future service	(29,295)	87,167	57,872
Income (loss) from insurance service	(147,736)	(66,709)	(214,445)
Insurance contract financial expenses	36,634	36,894	73,528
Balance at 12/31/2024	349,344	274,681	624,025
CSM recognized for services rendered	(27,162)	(43,165)	(70,327)
Changes regarding the current service	(27,162)	(43,165)	(70,327)
Contracts initially recognized in the period	-	231,201	231,201
Changes in the CMS adjusting estimates	14,876	(78,878)	(64,002)
Changes regarding the future service	14,876	152,323	167,199
Income (loss) from insurance service	(12,286)	109,158	96,872
Insurance contract financial expenses	10,330	11,026	21,356
Balance at 03/31/2025	347,388	394,865	742,253



## Notes to the financial statements

Notes to the individual and consolidated, condensed interim financial statements

March 31, 2025 and 2024, and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

## 13. Tax obligations

	Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
<b>Income tax and social contribution payable<sup>1</sup></b>	<b>5,915</b>	<b>15,952</b>	<b>6,299</b>	<b>16,735</b>
IRPJ	4,197	10,827	4,498	11,406
CSLL	1,718	5,125	1,801	5,329
<b>Other federal tax liabilities</b>	<b>19,824</b>	<b>21,321</b>	<b>24,875</b>	<b>27,830</b>
COFINS	5,683	5,303	6,117	5,749
PIS	923	862	1,009	950
PIS, COFINS and CSLL (PCC)	1,149	1,898	1,205	1,978
IRRF	7,577	8,770	7,852	9,274
IVA <sup>2</sup>	-	-	2,051	2,937
Other	121	9	470	359
Charges payable (social charges)	4,371	4,479	6,171	6,583
<b>Municipal tax liabilities</b>	<b>3,007</b>	<b>2,713</b>	<b>3,503</b>	<b>3,338</b>
	<b>28,746</b>	<b>39,986</b>	<b>34,677</b>	<b>47,903</b>
Current liabilities	28,746	39,986	34,383	47,600
Non-current liabilities	-	-	294	303
	<b>28,746</b>	<b>39,986</b>	<b>34,677</b>	<b>47,903</b>

<sup>1</sup> The Company adopts the annual taxable income regime, paying the amount monthly based on the suspension and reduction balance sheets, through advance payment of taxes. This modality is directly related to the performance of the result for the period.

<sup>2</sup> Value Added Tax from subsidiary Odontored.

## 14. Other accounts payable

	Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
<b>Sundry provisions</b>	<b>6,651</b>	<b>10,930</b>	<b>6,765</b>	<b>11,074</b>
IT support and service	4,335	5,764	4,335	5,764
Services	1,412	3,416	1,522	3,560
Marketing actions	699	1,750	699	1,750
Dental material	205	-	205	-
Insurance	-	-	4	-
<b>Advances from clients</b>	<b>-</b>	<b>941</b>	<b>891</b>	<b>1,600</b>
<b>Investments payable</b>	<b>7,962</b>	<b>7,844</b>	<b>8,551</b>	<b>8,415</b>
<b>Repurchase of shares payable</b>	<b>-</b>	<b>2,419</b>	<b>-</b>	<b>2,419</b>
<b>Long-term incentive</b>	<b>22,576</b>	<b>18,737</b>	<b>24,789</b>	<b>20,487</b>
<b>Credits to be identified<sup>1</sup></b>	<b>8,625</b>	<b>12,649</b>	<b>9,698</b>	<b>15,184</b>
<b>Unearned revenue (CPC 47/IFRS 15)</b>	<b>-</b>	<b>-</b>	<b>3,138</b>	<b>2,777</b>
<b>Outros<sup>2</sup></b>	<b>3,972</b>	<b>3,668</b>	<b>5,060</b>	<b>4,819</b>
	<b>49,786</b>	<b>57,188</b>	<b>58,892</b>	<b>66,775</b>
Current liabilities	24,835	36,076	31,315	43,514
Non-current liabilities	24,951	21,112	27,577	23,261
	<b>49,786</b>	<b>57,188</b>	<b>58,892</b>	<b>66,775</b>

<sup>1</sup>Correspond to amounts received from clients still unidentified.

<sup>2</sup>It refers mainly to revenues from post-payment contracts.

## Notes to the financial statements

## Notes to the individual and consolidated, condensed interim financial statements

March 31, 2025 and 2024, and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

## 15. Non-current liabilities

## 15.1. Provision for lawsuits

	Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
Provision for tax, labor and civil lawsuits	74,617	67,227	78,155	71,285
Other liabilities	14,897	14,767	15,498	15,351
Fees payable	91	-	91	-
	<b>89,605</b>	<b>81,994</b>	<b>93,744</b>	<b>86,636</b>

## 15.2. Provision for tax, labor and civil lawsuits

Changes	Company				
	Tax	Civil		Social security and labor	
		ANS <sup>1</sup>	Other		
Opening balance	28,882	29,608	7,433	1,304	67,227
Formation	332	1,132	7,289	19	8,772
Write-offs (payments/reversals)	(131)	(275)	(3,459)	-	(3,865)
Inflation adjustment	633	1,411	373	66	2,483
Provision	<b>29,716</b>	<b>31,876</b>	<b>11,636</b>	<b>1,389</b>	<b>74,617</b>
Number of lawsuits					1,445

<sup>1</sup> This is a Tax Assessment Notices drawn up by the ANS whose purpose is the non-payment of reimbursement for treatments performed at free choice by beneficiaries linked to certain products, mapped and monitored internally.

Changes	Consolidated				
	Tax	Civil		Social security and labor	
		ANS <sup>1</sup>	Other		
Opening balance	30,185	29,609	7,446	4,045	71,285
Formation	331	1,131	7,528	331	9,321
Write-offs (payments/reversals)	(133)	(275)	(3,706)	(977)	(5,091)
Inflation adjustment	635	1,411	373	221	2,640
Provision	<b>31,018</b>	<b>31,876</b>	<b>11,641</b>	<b>3,620</b>	<b>78,155</b>
Number of lawsuits					1,462

<sup>1</sup> This is a Tax Assessment Notices drawn up by the ANS whose purpose is the non-payment of reimbursement for treatments performed at free choice by beneficiaries linked to certain products, mapped and monitored internally.

As of March 31, 2025, the amounts related to possible losses not provided for in the Company and its Subsidiaries totaled (i) R\$ 4,837 - 69 labor lawsuits (R\$ 2,653 - 60 lawsuits in 2024); (ii) R\$ 94,816 - 3,305 civil lawsuits (R\$ 89,152 - 3,304 in 2024); and (iii) R\$ 74,952 - 51 tax lawsuits (R\$ 73,756 - 50 in 2024).

## Notes to the financial statements

## Notes to the individual and consolidated, condensed interim financial statements

March 31, 2025 and 2024, and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

## 16. Lease liabilities – CPC 06 (R2)/IFRS 16

The Company and its subsidiaries recognized lease liabilities related to the rental of real estate properties and equipment in accordance with the assumptions in CPC 06 (R2)/IFRS 16 – Leases. These liabilities were measured considering the present value of future lease payments, discounted using the average rate of 11.61% (11.58% as of December 31, 2024), and the corresponding entry was recorded as right of use in assets. The total impacts measured are presented below:

Company									
	12/31/2023	Remeasurement and new contracts	Payments	Allocation of financial charge	12/31/2024	Remeasurement and new contracts	Payments	Allocation of financial charge	03/31/2025
Real estate	15,107	631	(3,276)	956	13,418	3	(699)	221	12,943
Total	15,107	631	(3,276)	956	13,418	3	(699)	221	12,943
Current liabilities					1,958				1,984
Non-current liabilities					11,460				10,959
					13,418				12,943
Consolidated									
	12/31/2023	Remeasurement and new contracts	Payments	Allocation of financial charge	12/31/2024	Remeasurement and new contracts	Payments	Allocation of financial charge	03/31/2025
Real estate	28,755	1,143	(6,732)	2,259	25,425	1,611	(2,077)	527	25,486
Equipment	541	-	(242)	61	360	-	(60)	7	307
Total	29,296	1,143	(6,974)	2,320	25,785	1,611	(2,137)	534	25,793
Current liabilities					6,775				7,027
Non-current liabilities					19,010				18,766
					25,785				25,793

As of March 31, 2025, the aging of the lease liabilities is as follows:

Company								
	≤01 year	01–05 years	>05 years	12/31/2024	≤01 year	01–05 years	>05 years	03/31/2025
Real estate	1,958	9,897	1,563	13,418	1,984	9,397	1,562	12,943
<b>Total</b>	<b>1,958</b>	<b>9,897</b>	<b>1,563</b>	<b>13,418</b>	<b>1,984</b>	<b>9,397</b>	<b>1,562</b>	<b>12,943</b>

Consolidated								
	≤01 year	01–05 years	>05 years	12/31/2024	≤01 year	01–05 years	>05 years	03/31/2025
Real estate	6,571	17,291	1,563	25,425	6,822	17,102	1,562	25,486
Equipment	204	156	-	360	205	102	-	307
<b>Total</b>	<b>6,775</b>	<b>17,447</b>	<b>1,563</b>	<b>25,785</b>	<b>7,027</b>	<b>17,204</b>	<b>1,562</b>	<b>25,793</b>

## Notes to the financial statements

### Notes to the individual and consolidated, condensed interim financial statements

March 31, 2025 and 2024, and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

## 17. Shareholders' equity

### 17.1. Capital

	Company and Consolidated	
	03/31/2025	12/31/2024
Subscribed and paid-in capital (in thousands of reais)	851,017	851,017
Number of common shares, without par value (number of shares)	552,495,663	552,495,663
Article 7 of Bylaws - authorization for the issuance of shares, without amendment to the Bylaws (number of shares)	80,000,000	80,000,000
Closing quotation: ODPV3 - B3 SA Brasil Bolsa Balcão (R\$/share)	10.44	10.86
Equity value (R\$/share)	2.57	2.33

### 17.2. Capital reserves

**Other capital reserves:** goodwill/negative goodwill in capital transaction.

### 17.3. Profit reserves

	Company and Consolidated	
	03/31/2025	12/31/2024
Legal reserve	127,428	127,428
Statutory Reserve of Regulatory Capital	100,000	100,000
Investment and expansion statutory reserve	183,733	183,733
Tax incentive reserve	129	129
Additional dividend proposed	81,000	81,000
	<b>492,290</b>	<b>492,290</b>

### 17.4. Treasury shares

On a timely manner, the Company carries out Share Repurchase Programs which, in addition to regular payments of interest on own capital and dividends, have the objective of maximizing the generation of value for shareholders.

At a meeting on February 28, 2024, the Board of Directors approved a new Repurchase Program, the fourth since 2021, totaling 10 million shares, representing 3.9% of shares outstanding on the market, including within a period of up to 18 months, ending on August 29, 2025.

Up to March 31, 2025, the shares repurchased by the Program had an average nominal cost of R\$ 11.46 per share and an average price adjusted for dividends of R\$ 10.61, totaling R\$ 79,436 thousand (R\$ 71,572 thousand as of December 31, 2024) and 6,930,377 Treasury shares at the end of the period.

## Notes to the financial statements

## Notes to the individual and consolidated, condensed interim financial statements

March 31, 2025 and 2024, and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

## 17.5. Resolutions

Company						
Resolution				Payment date	Payment date	
Approval	Type	Date	Dividend per share (R\$)		03/31/2025	12/31/2024
RCA	Interest on own capital	03/27/2024	0.04137	08/21/2024	-	22,779
RCA	Interest on own capital	06/17/2024	0.03953	01/29/2025	-	21,642
RCA	Interest on own capital	09/26/2024	0.03360	04/03/2025	-	18,392
RCA	Interest on own capital	12/17/2024	0.03919	12/10/2025	-	21,423
RCA	Interest on own capital	03/19/2025	0.04536	12/10/2025	24,749	-
			<b>Interest on own capital</b>		<b>24,749</b>	<b>84,236</b>
RCA	Dividends	05/07/2024	0.13333	12/18/2024	-	73,000
RCA	Dividends	08/06/2024	0.15615	04/03/2025	-	85,478
RCA	Dividends	08/06/2024	0.22567	04/03/2025	-	123,427
			<b>Interim dividends</b>		-	<b>281,905</b>
AGM	Additional dividend proposed	02/26/2025	0.14840	12/10/2025	-	81,000
			<b>Additional dividend</b>		-	<b>81,000</b>
			<b>Total deliberated earnings</b>		<b>24,749</b>	<b>447,141</b>

RCA = Board of Directors' Meeting.

AGM = Ordinary General Meeting.

## 18. Operating segments

The activities of the Company and its subsidiaries are organized in the following business segments:

- (a) Corporate: includes clients over 200 beneficiaries;
- (b) SMALL AND MEDIUM-SIZED ENTERPRISE (SME): clients sized between 3 and 199 beneficiaries;
- (c) Individual: monthly and annual plans sold to individuals; and
- (d) Other: segments with less representation in the Company's total revenues, as follows: (i) dental care service in the Company's dental clinics (Clidec and Boutique Dental); (ii) management and advisory services provided (Odontoprev Serviços and Oprev); (iii) acquisition and distribution of dental care materials for the accredited network (Dental Partner); (iv) software development (Easy), (v) health insurance (Odontored); and (vi) imaging diagnosis (Papaiz).

Contribution margin - Consolidated										
CORPORATE		SME		INDIVIDUAL		OTHER		TOTAL		
Period ended		Period ended		Period ended		Period ended		Period ended		
03/31/2025	03/31/2024	03/31/2025	03/31/2024	03/31/2025	03/31/2024	03/31/2025	03/31/2024	03/31/2025	03/31/2024	03/31/2024
Insurance revenue (Premium Allocation Approach - PAA)	314,866	291,636	128,601	118,097	-	-	4,512	13,147	447,979	422,880
Insurance revenue (Building Block Approach - BBA)	-	-	-	-	129,333	121,373	-	-	129,333	121,373
<b>Insurance and reinsurance revenue</b>	<b>314,866</b>	<b>291,636</b>	<b>128,601</b>	<b>118,097</b>	<b>129,333</b>	<b>121,373</b>	<b>4,512</b>	<b>13,147</b>	<b>577,312</b>	<b>544,253</b>
Sales of goods and services	-	-	-	-	-	-	13,737	13,871	13,737	13,871
Taxes on sales of goods and services	-	-	-	-	-	-	(3,249)	(3,623)	(3,249)	(3,623)
<b>Revenue from sales of goods and services</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>10,488</b>	<b>10,248</b>	<b>10,488</b>	<b>10,248</b>
<b>SALES REVENUE</b>	<b>314,866</b>	<b>291,636</b>	<b>128,601</b>	<b>118,097</b>	<b>129,333</b>	<b>121,373</b>	<b>15,000</b>	<b>23,395</b>	<b>587,800</b>	<b>554,501</b>
Events occurred	(126,716)	(153,444)	(20,400)	(7,007)	(16,154)	(18,389)	(2,250)	(2,863)	(165,520)	(181,703)
Costs of purchase	(20,775)	(21,625)	(14,777)	(13,593)	(20,053)	(21,440)	(708)	(1,662)	(56,313)	(58,320)
Tax expenses	(14,234)	(12,295)	(6,890)	(6,206)	(7,434)	(7,023)	-	-	(28,558)	(25,524)
<b>OPERATING INCOME</b>	<b>153,141</b>	<b>104,272</b>	<b>86,534</b>	<b>91,291</b>	<b>85,692</b>	<b>74,521</b>	<b>12,042</b>	<b>18,870</b>	<b>337,409</b>	<b>288,954</b>
<b>CONTRIBUTION MARGIN</b>	<b>153,141</b>	<b>104,272</b>	<b>86,534</b>	<b>91,291</b>	<b>85,692</b>	<b>74,521</b>	<b>12,042</b>	<b>18,870</b>	<b>337,409</b>	<b>288,954</b>
Sales revenue (%)	54.5	53.6	22.3	21.7	22.4	22.3	2.6	4.3	100.0	100.0
Margin x sales revenue (%)	48.6	35.8	67.3	77.3	66.3	61.4	80.3	80.7	57.4	52.1
Distribution of margin x total/segment (%)	45.4	36.1	25.6	31.6	25.4	25.8	3.6	6.5	100.0	100.0

## Notes to the financial statements

## Notes to the individual and consolidated, condensed interim financial statements

March 31, 2025 and 2024, and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

## 19. Sales revenue

	Company		Consolidated	
	Period ended		Period ended	
	03/31/2025	03/31/2024	03/31/2025	03/31/2024
Considerations attributed to the PAA (Premium Allocation Approach) period	443,468	409,734	447,979	422,880
Revenues related to BBA (Building Block Approach) contracts	31,432	29,261	31,432	29,262
Change in the risk adjustment for non-financial risk	1,695	1,535	1,695	1,535
CSM recognized for services rendered	70,327	69,391	70,327	69,391
Recovery of acquisition cash flow	25,879	21,185	25,879	21,185
<b>Insurance and reinsurance revenue</b>	<b>572,801</b>	<b>531,106</b>	<b>577,312</b>	<b>544,253</b>
Sale of goods and services	-	-	13,737	13,871
Taxes on sales of goods and services	-	-	(3,249)	(3,623)
	<b>572,801</b>	<b>531,106</b>	<b>587,800</b>	<b>554,501</b>

## 20. Insurance expenses

	Company		Consolidated	
	Year ended		Year ended	
	03/31/2025	03/31/2024	03/31/2025	03/31/2024
Events occurred	(168,262)	(184,712)	(165,520)	(181,703)
Costs of purchase	(56,659)	(56,673)	(56,313)	(58,320)
Tax expenses	(28,558)	(25,524)	(28,558)	(25,524)
Administrative expenses	(81,549)	(80,098)	(81,709)	(79,923)
	<b>(335,028)</b>	<b>(347,007)</b>	<b>(332,100)</b>	<b>(345,470)</b>

## 21. Financial income (loss)

	Company		Consolidated	
	Period ended		Period ended	
	03/31/2025	03/31/2024	03/31/2025	03/31/2024
Yields from interest earning bank deposits	27,413	28,597	28,358	29,452
Inflation adjustment on judicial deposits	670	561	674	571
Inflation adjustment on tax credits <sup>1</sup>	1,075	3,449	1,095	3,449
Interest for late receipt <sup>2</sup>	961	2,120	962	2,123
Other	1,021	651	1,162	651
<b>Finance revenues</b>	<b>31,140</b>	<b>35,378</b>	<b>32,251</b>	<b>36,246</b>
Bank fees	(1,196)	(1,236)	(1,217)	(1,257)
Adjustment to present value - lease liabilities (CPC 06 (R2)/IFRS 16)	(221)	(251)	(534)	(618)
Inflation adjustment of provision for judicial contingencies	(2,483)	(1,085)	(2,640)	(1,112)
Discounts granted	(449)	(236)	(504)	(236)
Interest accreditation (CPC 50 / IFRS 17)	(10,753)	(8,452)	(10,753)	(8,452)
Other financial expenses	(1,037)	(624)	(1,433)	(946)
<b>Financial expenses</b>	<b>(16,139)</b>	<b>(11,884)</b>	<b>(17,081)</b>	<b>(12,621)</b>
	<b>15,001</b>	<b>23,494</b>	<b>15,170</b>	<b>23,625</b>

<sup>1</sup> In 2024, it mainly refers to update of Employer INSS credits, in which Odontoprev (which merged Rede Dental) received a final and unappealable decision in the lawsuit, securing its right to offset social security contributions unduly collected by Rede Dental on payments made to individual dentists between October 2007 to October 2019 (period after acquisition by Odontoprev).

<sup>2</sup> Refers mainly to the recognition of interest on individual/family plans.

## Notes to the financial statements

Notes to the individual and consolidated, condensed interim financial statements

March 31, 2025 and 2024, and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

## 22. Calculation of IRPJ/CSLL

	Company		Consolidated	
	Period ended		Period ended	
	03/31/2025	03/31/2024	03/31/2025	03/31/2024
Effect (CPC 50 / IFRS 17) before IRPJ and CSLL	5,517	(13,458)	4,769	(13,068)
IRPJ and CSLL calculation basis	239,681	221,666	242,044	223,941
	<b>245,198</b>	<b>208,208</b>	<b>246,813</b>	<b>210,873</b>
(x) Current rate (%)	34	34	34	34
<b>Estimate of IRPJ and CSLL expenses, according to the current rate</b>	<b>(83,367)</b>	<b>(70,791)</b>	<b>(83,916)</b>	<b>(71,697)</b>
Effect of Corporate Income Tax and Social contribution on permanent/temporary differences:				
Equity in net income of subsidiaries	1,171	1,754	561	434
Provision for lawsuits	(2,242)	(743)	(2,065)	(777)
Sundry provisions	1,424	910	1,420	915
Amortization of goodwill	457	487	551	487
Profit sharing	(1,751)	(1,874)	(1,980)	(2,153)
Interest on own capital	8,415	7,745	8,415	7,745
Adjustments - Law 12973/14	(1)	(13)	(8)	(12)
Tax losses	-	-	(967)	-
Effect (CPC 50 / IFRS 17)	1,876	(4,575)	1,621	(4,443)
Insurance Expenses   Acquisition Costs and ILP Program	15,819	(1,608)	15,674	(1,731)
Other	166	474	11	76
<b>Current IRPJ and CSLL expense</b>	<b>(58,033)</b>	<b>(68,234)</b>	<b>(60,683)</b>	<b>(71,156)</b>
Deferred IRPJ and CSLL revenue (expense)	(15,016)	1,953	(14,884)	2,552
Deferred IRPJ and CSLL revenue (CPC 50 / IFRS 17)	(2,425)	4,810	(1,677)	4,420
<b>Deferred IRPJ and CSLL expense</b>	<b>(17,441)</b>	<b>6,763</b>	<b>(16,561)</b>	<b>6,972</b>
<b>Total IRPJ and CSLL expense</b>	<b>(75,474)</b>	<b>(61,471)</b>	<b>(77,244)</b>	<b>(64,184)</b>
Effective rate	30.8%	29.5%	31.3%	30.4%

## 23. Earnings per share – basic and diluted

	Period ended	
	03/31/2025	03/31/2024
Income attributable to Company's shareholders (in thousands of reais)	169,724	146,737
Common shares (in thousands)		
Weighted average number of common shares issued (thousands)	545,782	552,496
<b>Weighted average number of shares for the basic and diluted earnings per share</b>	<b>545,782</b>	<b>552,496</b>
<b>Basic and diluted earnings per share (R\$)</b>	<b>0.31097</b>	<b>0.26559</b>

## Notes to the financial statements

## Notes to the individual and consolidated, condensed interim financial statements

March 31, 2025 and 2024, and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

## 24. Related parties

Related party transactions are carried out at values, terms and average rates in line with the ones practiced with third parties (if any), in force on the respective dates.

Operations of the Company with its Subsidiaries, Associated Companies and Key Management Personnel (Note 1)	Classification   Nature	03/31/2025		12/31/2024		Period ended 03/31/2025		Period ended 03/31/2024	
		Assets		Assets		Revenue		Expense	
		Assets	Liabilities	Assets	Liabilities	Revenue	Expense	Revenue	Expense
DentalPartner	Sales of goods and services   Dental materials	76	-	76	-	521	-	739	-
Odontoprev	Administrative expenses   Administrative services	-	76	-	76	-	(17,335)	-	(17,727)
Odontoprev Serviços	Sales of goods and services   Commercial advisory	952	-	717	-	14,229	-	16,557	-
Odontoprev Serviços	Administrative expenses   Dental Assistance	-	-	-	-	-	(27)	-	(9)
Brasilidental	Insurance Expenses   Administrative Services	-	961	-	726	-	(3,082)	-	(3,624)
Odontoprev	Considerations   Dental plans	-	-	-	-	50	-	22	-
Odontoprev	Considerations   Assumed/ceded co-responsibility	4,509	-	4,346	-	12,449	-	12,303	-
Odontoprev	Other operating revenues   Revenues from healthcare plans	9	-	9	-	55	-	46	-
Brasilidental	Insurance expenses   Assumed/ceded co-responsibility	-	4,509	-	4,346	-	(12,449)	-	(12,303)
Clidec	Administrative expenses   Dental Assistance	-	-	-	-	-	(13)	-	(12)
Clidec	Sales of goods and services   Clinical dental services	-	-	-	-	8,478	-	6,796	-
Boutique Dental	Sales of goods and services   Clinical dental services	-	-	-	-	875	-	1,055	-
Papaiz	Sales of goods and services   Radiology services	-	-	-	-	1,642	-	1,316	-
Papaiz	Administrative expenses   Dental Assistance	-	-	-	-	-	(10)	-	-
Odontoprev	Known or reported events/claims   Dental services	-	-	-	-	-	(4,832)	-	(4,399)
Odontoprev	Other healthcare expenses   Dental care materials	-	-	-	-	-	(521)	-	(739)
Easy	Administrative expenses   Dental Assistance	-	-	-	-	-	(1)	-	(1)
Easy	Administrative expenses   Administrative services	-	-	-	-	-	(29)	-	(20)
Odontoprev	Dividends receivable	5,500	-	-	-	-	-	-	-
Odontoprev Serviços	Dividends payable	-	3,500	-	-	-	-	-	-
Clidec	Dividends payable	-	2,000	-	-	-	-	-	-
MaChiron	Intangible asset   System development	2,412	-	2,056	-	-	-	-	-
Key management personnel	Insurance Revenue   Dental Plans	-	-	-	-	2	-	-	-
<b>Total</b>		<b>13,458</b>	<b>11,046</b>	<b>7,204</b>	<b>5,148</b>	<b>38,301</b>	<b>(38,299)</b>	<b>38,834</b>	<b>(38,834)</b>

The Company and its Subsidiaries conduct transactions with companies of Bradesco Organization, of which Bradesco Saúde, shareholder of Odontoprev, is part:



## Notes to the financial statements

## Notes to the individual and consolidated, condensed interim financial statements

March 31, 2025 and 2024, and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

Consolidated - Year ended:									
Companies related to the Bank	Classification   Nature	03/31/2025		12/31/2024		03/31/2025		03/31/2024	
		Assets	Liabilities	Assets	Liabilities	Revenue	Expense	Revenue	Expense
Alelo S.A.	Insurance Expenses   Employee Benefits	-	-	-	33	-	(1,269)	-	(1,345)
Banco Bradescard S.A.	Insurance Expenses   Acquisition Cost	13	726	29	11	-	(2,333)	-	(39)
Banco Bradesco S.A.	Current account	4,435	-	6,713	-	-	-	-	-
Banco Bradesco S.A.	Interest earning bank deposit	1,005,813	-	887,225	-	27,299	-	28,492	-
Banco Bradesco S.A.	Insurance Revenue   Dental Plans	10	-	10	-	12,433	-	12,647	-
Banco Bradesco S.A.	Insurance expenses   Travel and accommodation - officers and employees	-	-	-	-	-	(525)	-	(355)
Banco Bradesco S.A.	Financial Expenses   Bookkeeping of shares	-	-	-	-	-	(99)	-	(68)
Banco Bradesco S.A.	Insurance Expenses   Rentals of branches	-	-	-	-	-	(87)	-	(74)
Banco Bradesco S.A.	Financial Expenses   Investment management	-	-	-	-	-	(98)	-	(100)
Banco Bradesco S.A.	Financial expenses   Bank fee	-	-	-	-	-	(930)	-	(955)
Banco Bradesco S.A.	Right-of-use and lease liability	1,522	1,331	-	-	-	(924)	-	(66)
Bradesco Auto-Re Companhia De Seguros	Insurance Expenses   Civil liability Insurance and insurance guarantee	-	-	-	-	-	(7)	-	-
Bradesco S/A Corretora De Títulos E Valores Mobiliários	Insurance Expenses   Acquisition Cost	-	-	-	2,419	-	(3)	-	(6)
Bradesco Capitalização S.A.	Special savings bonds	5,371	-	4,360	-	-	-	-	-
Bradesco Saúde S.A.	Insurance Expenses   Medical Assistance - Employees	-	-	-	-	-	(4,385)	-	(4,475)
Bradesco Saúde S.A.	Dividends and interest on own capital	-	144,638	-	142,994	-	-	-	-
Bradesco Vida e Previdência S.A.	Insurance Expenses   Private pension - employees	-	-	-	-	-	(434)	-	(361)
Bradesco Vida e Previdência S.A.	Insurance expenses   Life insurance - Employees	-	30	-	-	-	(63)	-	(127)
Bradesco Corretora de Seguros Ltda.	Insurance Expenses   Acquisition Cost	48	452	74	1,594	-	(608)	-	(35)
Bradseg Promotora de Vendas S.A.	Insurance Expenses   Acquisition Cost	225	4,482	334	8,323	-	(5,946)	-	(8,714)
Braspag -Tecnologia em Pagamento Ltda.	Insurance Expenses   Financial Services	-	-	-	-	-	-	-	(152)
Brésia Empreendimentos E Participações Ltda.	Insurance Expenses   Rentals of branches	-	-	-	-	-	(5)	-	(5)
Bsp Empreendimento Imobiliário D166 Ltda.	Insurance Expenses   Rentals of branches	-	-	-	-	-	(17)	-	(15)
Bsp Empreendimento Imobiliário D166 Ltda.	Right-of-use and lease liability	887	683	-	-	-	(546)	-	(34)
Bsp Empreendimento Imobiliário Ltda.	Right-of-use and lease liability	521	425	-	-	-	(319)	-	(20)
Bsp Park Estacionamentos E Participações S.A.	Insurance Expenses   Parking	-	-	-	-	-	(1)	-	(2)
Mediservice	Other Operating Revenues   Management Fee	-	-	-	-	74	-	99	-
Santecorp Holding Ltda	Insurance Expenses   Medical/Outpatient Services	-	-	-	-	-	(72)	-	(137)
Santecorp Holding Ltda	Insurance Revenue   Dental Plans	-	-	-	-	3	-	2	-
Stelo S.A.	Financial expenses   Management fee	-	-	-	-	-	(169)	-	-
Swiss Re Corporate Solutions Brasil Seguros S.A.	Insurance Expenses   Legal Guarantee Insurance	-	-	-	-	-	(67)	-	(58)
Banco Digio S.A.	Insurance Expenses   Acquisition Cost	-	4	1	8	-	(5)	-	-
Fleury CPMA	Insurance Revenue   Dental Plans	-	-	-	-	14	-	15	-
Fleury S.A.	Insurance Revenue   Dental Plans	-	-	-	-	784	-	764	-
Instituto de Radiologia de Natal Ltda.	Insurance Revenue   Dental Plans	-	-	-	-	11	-	11	-
Centro de Patologia Clínica Ltda.	Insurance Revenue   Dental Plans	-	-	-	-	2	-	1	-
Saúde Newco Ltda.	Insurance Revenue   Dental Plans	-	-	-	-	1	-	1	-
Methodos Laboratório, Análises Clínicas e Hematologia Ltda.	Insurance Revenue   Dental Plans	-	-	-	-	6	-	6	-
Genesis Análises Genômicas S.A.	Insurance Revenue   Dental Plans	-	-	-	-	17	-	-	-
Instituto Hermes Pardini S.A.	Insurance Revenue   Dental Plans	-	-	-	-	183	-	116	-
Laboratório Padrão S.A.	Insurance Revenue   Dental Plans	-	-	-	-	19	-	14	-
Diagnóstico Por Imagem Sete Lagoas Ltda.	Insurance Revenue   Dental Plans	-	-	-	-	1	-	-	-
Toxicologia Pardini Laboratórios S.A.	Insurance Revenue   Dental Plans	-	-	-	-	4	-	3	-
Laboratório de Patologia Clínica Dr Paulo C. de Azevedo	Insurance Revenue   Dental Plans	-	-	-	-	17	-	17	-
Instituto de Análises Clínicas de Santos	Insurance Revenue   Dental Plans	-	-	-	-	12	-	9	-
Anatomia Patológica Hugo Silviano Branda	Insurance Revenue   Dental Plans	-	-	-	-	1	-	1	-
Haitong Banco de Investimentos do Brasil S.A.	Insurance Revenue   Dental Plans	-	-	-	-	22	-	49	-
Bradescard México, Limited Liability Company	Insurance Expenses   Acquisition Cost	-	140	-	-	-	(521)	-	(625)
Key management personnel	Insurance Expenses   Acquisition Cost	6	1	5	-	-	(2)	-	(1)
Key management personnel	Insurance Revenue   Dental Plans	-	-	-	-	2	-	1	-
Key management personnel	Insurance Expenses   Administrative Expenses	-	-	-	-	-	(764)	-	(585)
Key management personnel	Intangible asset   System development	699	-	-	-	-	-	-	-
Key management personnel	Accounts payable   Service providers	-	48	-	-	-	-	-	-
Key management personnel	Insurance Expenses   Events occurred	-	-	-	-	-	(1)	-	-
Key management personnel	Insurance expenses   Consulting	-	-	-	-	-	(13)	-	-
		1,019,550	152,960	898,751	155,382	40,905	(20,213)	42,248	(18,354)

The Company contracted a court guarantee insurance related to the tax assessment notices on the stock options whose policies were contracted together with Swiss Re Corporate Solutions Brasil Seguros S.A. (Swiss Re Brasil) which maintains an investment with Bradesco Seguros S.A. (Bradesco Seguros).

The Company and its subsidiaries grant profit sharing to its employees and officers linked to the achievement of operating goals and specific objectives established and approved at the beginning of each year. As of March 31, 2025, the amounts of R\$ 5,149 (R\$ 5,511 as of March 31, 2024) and R\$ 6,220 (R\$ 6,620 as of March 31, 2024) were appropriated as profit sharing in the Company and in the Consolidated.

In 2019, the Company implemented a long-term incitement program (ILP Program), which establishes the criteria for the payment of cash bonuses, corresponding to salary multiples, to be made by the Company and its subsidiaries to the eligible beneficiaries after the measurement period, provided that the goals and conditions established in the terms are met.

The measurement period corresponds to three years and the payment is conditioned upon the achievement of the corporate performance targets established by the Board of Directors and the service condition.

As of March 31, 2025, R\$ 3,784 and R\$ 4,241 in the Company and Consolidated, respectively (R\$ 5,051 and R\$ 5,450 as of March 31, 2024) were appropriated to income (loss) for the period.

## Notes to the financial statements

### Notes to the individual and consolidated, condensed interim financial statements

March 31, 2025 and 2024, and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

The stock options program remains in effect, as approved by the GM with the last granting being made in 2016.

The annual fixed remuneration attributed to the Board of Directors and the Tax Council and the fixed/variable remuneration attributed to the Statutory Executive Board were as follows:

	Period ended	
	03/31/2025	03/31/2024
<b>Statutory Board</b>	<b>1,413</b>	<b>1,848</b>
Directors' fee	1,166	1,558
Benefits	177	205
Private pension	70	85
<b>Board of Directors</b>	<b>1,164</b>	<b>960</b>
Directors' fee	1,164	960
<b>Fiscal Council</b>	<b>131</b>	<b>131</b>
Directors' fee	131	131
	<b>2,708</b>	<b>2,939</b>

The Board of Directors and Tax Council, as well as the Personnel Management Committee, include members who are part of the management of Banco Bradesco S.A. and Bradesco Seguros.

The Company does not sponsor post-employment benefit (except for a supplementary pension plan) or any termination of employment contract.

## 25. Subsequent events

At the Annual General Meeting held on April 01, 2025, the Company informed its shareholders about the distribution of dividends in the total amount of R\$ 81,000 related to supplementary dividends (corresponding to R\$ 0.1484698570 per share), which will be paid on December 10, 2025.

On the same date, the cancellation of 6,670,377 treasury shares was approved at the Annual and Extraordinary General Meeting, bringing the total capital to 546 million shares.

In April 2025, we had 472 repurchased shares, totaling R\$ 5,025.

In a meeting held on May 06, 2025, the Board of Directors approved the distribution of dividends for the first quarter of 2025 in the amount of R\$ 118 million.

## Other information the Company deems to be relevant

SHAREHOLDING POSITION OF THE HOLDERS OF OVER 5% OF THE COMPANY'S SHARES						
Position as of 03/31/2025						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Bradesco Saúde S.A.	292,213,236	52.89	-	-	292,213,236	52.89
Sprucegrove Investment Management	27,671,300	5.01	-	-	27,671,300	5.01
Treasury shares	6,930,377	1.25	-	-	6,930,377	1.25
Outstanding shares	225,680,750	40.85	-	-	225,680,750	40.85
<b>Total</b>	<b>552,495,663</b>	<b>100.00</b>	-	-	<b>552,495,663</b>	<b>100.00</b>

BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: Bradesco Saúde S.A. Position as of 03/31/2025						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Bradesco Gestão de Saúde S.A.	20,870,945	100.00	-	-	20,870,945	100.00

BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: Bradesco Gestão de Saúde S.A. Position as of 03/31/2025						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Bradseg Participações S.A.	12,251,025,597	100.00	-	-	12,251,025,597	100.00
<b>Total</b>	<b>12,251,025,597</b>	<b>100.00</b>	-	-	<b>12,251,025,597</b>	<b>100.00</b>

BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: Bradseg Participações S.A. Position as of 03/31/2025						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Banco Bradesco S.A.	12,318	100.00	-	-	12,318	100.00
<b>Total</b>	<b>12,318</b>	<b>100.00</b>	-	-	<b>12,318</b>	<b>100.00</b>

\*according to the Reference Form of 4/11/2025, available on the RI website of Banco Bradesco.

BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: Banco Bradesco S.A.						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Cidade de Deus Cia Cial Participações	2,445,219,983	46.10	1,292,135	0.02	2,446,512,118	23.10
Fundação Bradesco	914,471,634	17.24	3	0.00	914,471,637	8.63
NCF Participações S.A.	451,890,822	8.52	119,774,968	2.26	571,665,790	5.40
Other	1,486,288,342	28.02	5,161,074,141	97.61	6,647,362,483	62.76
Treasury shares	6,000,000	0.11	6,000,000	0.11	12,000,000	0.11
<b>Total</b>	<b>5,303,870,781</b>	<b>100.00</b>	<b>5,288,141,247</b>	<b>100.00</b>	<b>10,592,012,028</b>	<b>100.00</b>

BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: Cidade de Deus Cia Cial Participações						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Fundação Bradesco	2,779,096,924	35.44	-	-	2,779,096,924	35.44
Nova Cidade de Deus Participações S.A.	3,758,724,093	47.93	-	-	3,758,724,093	47.93
Other	1,304,138,507	16.63	-	-	1,304,138,507	16.63
<b>Total</b>	<b>7,841,959,524</b>	<b>100.00</b>	-	-	<b>7,841,959,524</b>	<b>100.00</b>

BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: NCF Participações S.A.						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Cidade de Deus Cia Cial Participações	1,430,717,378	74.72	-	-	1,430,717,378	39.51
Fundação Bradesco	481,149,175	25.13	1,706,485,482	100.00	2,187,634,657	60.41
Nova Cidade de Deus Participações S.A.	2,864,526	0.15	-	-	2,864,526	0.08
<b>Total</b>	<b>1,914,731,079</b>	<b>100.00</b>	<b>1,706,485,482</b>	<b>100.00</b>	<b>3,621,216,561</b>	<b>100.00</b>

BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: Nova Cidade de Deus Participações S.A.						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
BBD Participações S.A.	189,425,112	53.70	-	-	189,425,112	26.07
Fundação Bradesco	163,332,621	46.30	373,794,914	100.00	537,127,535	73.93
<b>Total</b>	<b>352,757,733</b>	<b>100.00</b>	<b>373,794,914</b>	<b>100.00</b>	<b>726,552,647</b>	<b>100.00</b>

BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: BBD Participações S.A.						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Treasury shares	46,475,765	20.96	11,703,990	5.28	58,179,755	13.12
NCD Participações Ltda	67,114,094	30.27	141,898,399	64.05	209,012,493	47.15
Other	108,155,012	48.77	67,957,837	30.67	176,112,849	39.73
<b>Total</b>	<b>221,744,871</b>	<b>100.00</b>	<b>221,560,226</b>	<b>100.00</b>	<b>443,305,097</b>	<b>100.00</b>


BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: NCD Participações Ltda						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Fundação Bradesco	2,793,303,109	100.00	-	-	2,793,303,109	100.00
Other	1	0.00	-	-	1	0.00
<b>Total</b>	<b>2,793,303,110</b>	<b>100.00</b>	-	-	<b>2,793,303,110</b>	<b>100.00</b>

**Other information the Company deems to be relevant**

CONSOLIDATED SHAREHOLDING POSITION OF THE CONTROLLING SHAREHOLDERS AND DIRECTORS AND OFFICERS AND SHARES IN CIRCULATION						
Position as of 03/31/2025						
Shareholder	Number of Common Shares (Units)	%	Number of Preferred Shares (Units)	%	Total Number of Shares (Units)	%
Controlling managers	292,213,236	52.89	-	-	292,213,236	52.89
Managers	1,132,529	0.20	-	-	1,132,529	0.20
Treasury shares	6,930,377	1.25	-	-	6,930,377	1.25
Other	252,219,521	45.65	-	-	252,219,521	45.65
Total	552,495,663	100.00	-	-	552,495,663	100.00
Outstanding shares	252,219,521	45.65	-	-	252,219,521	45.65

CONSOLIDATED SHAREHOLDING POSITION OF THE CONTROLLING SHAREHOLDERS AND DIRECTORS AND OFFICERS AND SHARES IN CIRCULATION						
Position as of 03/31/2024						
Shareholder	Number of Common Shares (Units)	%	Number of Preferred Shares (Units)	%	Total Number of Shares (Units)	%
Controlling managers	292,213,236	52.89	-	-	292,213,236	52.89
Managers	1,390,659	0.25	-	-	1,390,659	0.25
Treasury shares	1,854,600	0.34	-	-	1,854,600	0.34
Other	257,037,168	46.52	-	-	257,037,168	46.52
Total	552,495,663	100.00	-	-	552,495,663	100.00
Outstanding shares	257,037,168	46.52	-	-	257,037,168	46.51

Other information the Company deems to be relevant



## Opinions and Statements / Special Review Report - Unqualified

To the Board of Directors and Shareholders of  
Odontoprev S.A.  
Barueri - SP

### Introduction

We have reviewed the interim, individual and consolidated, condensed financial information of Odontoprev S.A. ("Company"), contained in the Quarterly Information - ITR Form for the quarter ended March 31, 2025, which comprise the balance sheet on March 31, 2025 and related statements of income, of comprehensive income, of changes in shareholders' equity and of cash flows for the quarter then ended, including explanatory notes.

Company's Management is responsible for the preparation of the individual interim financial information in accordance with CPC 21 (R1) and the consolidated, condensed interim financial information in accordance with CPC 21 (R1) and with international standard IAS 34 - Interim Financial Reporting, issued by the International Accounting Standards Board - (IASB), as well as for the presentation of this information in a manner consistent with the standards issued by the Brazilian Securities and Exchange Commission, applicable to the preparation of the Quarterly Information (ITR). Our responsibility is to express a conclusion on these interim financial information based on our review.

### Scope of the review

Our review was carried out in accordance with the Brazilian and international review standards for interim information (NBC TR 2410 – Review of Interim Financial Information Performed by the Independent Auditor of the Entity and ISRE 2410 – Review of Interim Financial Information Performed by the Independent Auditor of the Entity, respectively). A review of interim information consists in asking questions, chiefly to the persons in charge of financial and accounting affairs, and in applying analytical procedures and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Brazilian and International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### Conclusion on the interim, individual condensed information

Based on our review, we are not aware of any facts that would lead us to believe that the interim, individual condensed financial information included in the quarterly information referred to above was not prepared, in all material respects, in accordance with CPC 21(R1) applicable to the preparation of Quarterly Information (ITR), and presented in a manner consistent with the standards issued by the Securities Commission.

### Conclusion on the interim, consolidated and condensed information

Based on our review, we are not aware of any facts that would lead us to believe that the interim consolidated, condensed financial information included in the quarterly information referred to above was not prepared, in all material respects, in accordance with CPC 21 (R1) and IAS 34, applicable to the preparation of Quarterly Information - ITR, and presented in a manner consistent with the standards issued by the Securities Commission.

### Other issues - Statements of added value

The aforementioned quarterly information includes the individual and consolidated statements of added value for the three-month period ended March 31, 2025, prepared under responsibility of Company's Management, and presented as supplementary information for IAS 34 purposes. These statements have been subject to review procedures performed in conjunction with the review of the quarterly information, in order to determine whether they are reconciled with the interim financial information and book records, as applicable, and whether their form and content are in accordance with the criteria defined in Technical Pronouncement CPC 09 – Statement of Added Value. Based on our review, we are not aware of any facts that may lead us to believe that those statements of added value have not been prepared, in all material respects, in accordance with the criteria set forth in this Standard and consistently with respect to the interim, individual and consolidated, condensed financial information taken as a whole.

São Paulo, May 6, 2025

KPMG Auditores Independentes Ltda.  
CRC 2SP-027685/O-0 F SP

Fernando Antonio Rodrigues Alfredo  
Accountant CRC 1SP252419/O-0

## **Opinions and Statements / Statement of the Executive Officers on the Financial Statements**

We declare, in our capacity as Statutory Directors of Odontoprev S.A., a joint stock company headquartered in the city of Barueri, state of São Paulo, at Alameda Araguaia, 2104, 21º Andar - Alphaville, CNPJ [EIN] 58.119.199/0001-51, pursuant to article 27, para. 1, item VI of CVM Resolution 80 of March 29, 2022, as amended, which we reviewed, discussed and agreed with the Financial Statements for the first quarter of 2025.

Barueri/SP, May 6, 2025

**Opinions and Statements / Statement of the Directors on Independent Auditor's Report**

We declare, in our capacity as Statutory Directors of Odontoprev S.A., a joint stock company headquartered in the city of Barueri, state of São Paulo, at Alameda Araguaia, 2104, 21º Andar - Alphaville, CNPJ [EIN] 58.119.199/0001-51, pursuant to article 27, para. 1, item V of CVM Resolution 80 of March 29, 2022, as amended, which we reviewed, discussed and agreed with the opinions expressed in the report of the independent auditors of the Company, KPMG Auditores Independentes Ltda., referring to the Company's 1Q25 quarterly earnings.

Barueri/SP, May 6, 2025